Document:

Exhibit 10.11

Execution Version

BMW VEHICLE LEASE TRUST 2017-2,

 as Issuer,

U.S. BANK NATIONAL ASSOCIATION,

 not in its individual capacity but solely as Indenture Trustee

and as Secured Party,

and

U.S. BANK NATIONAL ASSOCIATION,

as Securities Intermediary

                                                                      

______________________________________

CONTROL AGREEMENT

Dated as of October 25, 2017

______________________________________

 

                                                                      

 

TABLE OF CONTENTS

Page

 

	
Article One DEFINITIONS

	
1

 

	
Section 1.01.

 

	
General Definitions

	
1

	
Section 1.02.

 

	
Incorporation of UCC by Reference

	
2

	
Article Two ESTABLISHMENT OF CONTROL OVER SECURITIES ACCOUNTS

	
2

 

	
Section 2.01.

 

	
Establishment of the Accounts

	
2

	
Section 2.02.

 

	
“Financial Assets” Election

	
3

	
Section 2.03.

 

	
Entitlement Orders

	
3

	
Section 2.04.

 

	
Subordination of Lien; Waiver of Set-Off

	
3

	
Section 2.05.

 

	
Notice of Adverse Claims

	
3

	
Article Three REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE SECURITIES INTERMEDIARY

	
4

 

	
Section 3.01.

 

	
Representations, Warranties and Covenants of the Securities Intermediary

	
4

	
Article Four MISCELLANEOUS

	
5

 

	
Section 4.01.

 

	
Choice of Law

	
5

	
Section 4.02.

 

	
Conflict with other Agreements

	
5

	
Section 4.03.

 

	
Amendments

	
5

	
Section 4.04.

 

	
Successors

	
5

	
Section 4.05.

 

	
Notices

	
5

	
Section 4.06.

 

	
Termination

	
5

	
Section 4.07.

 

	
Counterparts

	
6

	
Section 4.08.

 

	
Limitation of Liability of Owner Trustee

	
6

	
Section 4.09.

 

	
Communications with Rating Agencies

	
6

i

CONTROL AGREEMENT

This Control Agreement, dated as of October 25, 2017 (this “Agreement”), is among BMW Vehicle Lease Trust 2017-2, as the issuer (the “Issuer”), U.S. Bank National Association, not in its individual capacity but solely as indenture trustee (in such capacity, the “Indenture Trustee”) and as secured party (in such capacity, the “Secured Party”), and U.S. Bank National Association, as securities intermediary (the “Securities Intermediary”).

RECITALS

WHEREAS, pursuant to the Indenture, the Issuer has granted to the Secured Party a security interest in investment property consisting of the 2017-2 SUBI Collection Account, the Reserve Fund, related Security Entitlements and the financial assets and other investment property from time to time included therein to secure payment of the Secured Obligations; and

WHEREAS, the parties hereto desire that the security interest of the Secured Party be a first priority security interest perfected by “control” pursuant to Articles Eight and Nine of the UCC.

NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

ARTICLE ONE

 DEFINITIONS

Section 1.01.        General Definitions.  Except as otherwise specified herein or as the context may otherwise require, the following terms have the respective meanings set forth below for all purposes of this Agreement.  Capitalized terms that are used herein that are not otherwise defined shall have the meaning ascribed thereto in the Indenture.

“2017-2 SUBI Collection Account” means a securities account (within the meaning of Section 8-501 of the UCC) in the name “BMW Vehicle Lease Trust 2017-2” established with the Securities Intermediary pursuant to the Indenture, together with any successor accounts established pursuant to the Indenture.

“Accounts” means the 2017-2 Collection Account and the Reserve Fund.

“Agreement” has the meaning set forth in the Preamble.

“Entitlement Holder” means, with respect to any financial asset, a Person identified in the records of the Securities Intermediary as the Person having a Security Entitlement against the Securities Intermediary with respect to such financial asset.

“Entitlement Order” means a notification directing the Securities Intermediary to transfer or redeem a financial asset.

“Hague Securities Convention” means The Convention on the Law Applicable to Certain Rights in Respect of Securities Held with an Intermediary (Concluded 5 July 2006), which became effective in the United States of America on April 1, 2017.

“Indenture” means the Indenture, dated as of October 25, 2017, between the Issuer and the Indenture Trustee.

“Indenture Trustee” has the meaning set forth in the Preamble.

“Issuer” has the meaning set forth in the Preamble.

“Notes” has the meaning set forth in the Indenture.

“Person” means any individual, corporation, estate, partnership, joint venture, association, joint stock company, trust (including any beneficiary thereof), unincorporated organization or government or any agency or political subdivision thereof.

“Reserve Fund” means a securities account (within the meaning of Section 8-501 of the UCC) in the name “U.S. Bank National Association, as Indenture Trustee, BMW Vehicle Lease Trust 2017-2” established with the Securities Intermediary pursuant to the Indenture, together with any successor accounts established pursuant to the Indenture.

“Secured Obligations” means the payments required to be made to Securityholders pursuant to Section 8.04 and Article V of the Indenture.

“Secured Party” has the meaning set forth in the Preamble.

“Security Entitlement” means the rights and property interest of an Entitlement Holder with respect to a financial asset, as specified in Part 5 of Article 8 of the UCC.

“UCC” means the Uniform Commercial Code as in effect in the State of New York on the date hereof.

Section 1.02.        Incorporation of UCC by Reference.  Except as otherwise specified herein or as the context may otherwise require, all terms used in this Agreement not otherwise defined herein which are defined in the UCC shall have the meanings assigned to them in the UCC.

ARTICLE TWO

 ESTABLISHMENT OF CONTROL OVER SECURITIES ACCOUNTS

Section 2.01.        Establishment of the Accounts.  The Securities Intermediary hereby confirms that (i) the Accounts have been established with the Securities Intermediary, (ii) each Account is an account to which financial assets are or may be credited, (iii) the Securities Intermediary shall, subject to the terms of this Agreement and the Indenture, treat the Secured Party as entitled to exercise the rights that comprise any financial asset credited to an Account, (iv) all property delivered to the Securities Intermediary by or on behalf of the Secured Party or

2

the Issuer for deposit to an Account will promptly be credited to such Account and (v) all securities or other property underlying any financial assets credited to an Account shall be registered in the name of the Securities Intermediary, endorsed to the Securities Intermediary or in blank or credited to another securities account maintained in the name of the Securities Intermediary and in no case will any financial asset credited to an Account be registered in the name of the Issuer, payable to the order of the Issuer or specially endorsed to the Issuer except to the extent the foregoing have been specially endorsed to the Securities Intermediary or in blank.

Section 2.02.        “Financial Assets” Election.  The Securities Intermediary hereby agrees that each item of property (whether investment property, financial asset, security, instrument or cash) credited to the Accounts shall be treated as a “financial asset” within the meaning of Section 8-102(a)(9) of the UCC.

Section 2.03.        Entitlement Orders.  If at any time the Securities Intermediary shall receive any Entitlement Order from the Secured Party with respect to an Account, the Securities Intermediary shall comply with such Entitlement Order without further consent by the Issuer or any other Person.  If at any time the Secured Party notifies the Securities Intermediary in writing that the lien of the Indenture has been released, the Securities Intermediary shall thereafter comply with Entitlement Orders with respect to such Account from the Issuer without further consent by the Issuer or any other Person.

Section 2.04.        Subordination of Lien; Waiver of Set-Off.  In the event that the Securities Intermediary has or subsequently obtains by agreement, operation of law or otherwise a security interest in the Accounts or any Security Entitlement credited thereto, the Securities Intermediary hereby agrees that such security interest shall be subordinate to the security interests of the Secured Party and the Issuer.  The financial assets and other items deposited to an Account will not be subject to deduction, set-off, banker’s lien or any other right in favor of any Person or entity other than the Secured Party and, subject to the provisions hereof, the Issuer (except that the Securities Intermediary may set off against amounts on deposit in such Account (i) all amounts due to it in respect of its customary fees and expenses for the routine maintenance and operation of such Account, and (ii) the face amount of any checks which have been credited to such Account but are subsequently returned unpaid because of uncollected or insufficient funds).

Section 2.05.        Notice of Adverse Claims.  Except for the claims and interests of the Issuer and the Secured Party in the Accounts, the Securities Intermediary does not know of any claim to, or interest in, the Accounts or in any financial asset credited thereto.  If any Person asserts any lien, encumbrance or adverse claim (including any writ, garnishment, judgment, warrant of attachment, execution or similar process) against an Account or in any financial asset carried therein, the Securities Intermediary will promptly notify the Secured Party and the Issuer thereof.

3

ARTICLE THREE

REPRESENTATIONS, WARRANTIES AND COVENANTS

 OF THE SECURITIES INTERMEDIARY

Section 3.01.        Representations, Warranties and Covenants of the Securities Intermediary.  The Securities Intermediary hereby represents and warrants to the Secured Party and the Issuer, and covenants that:

(a)            Each Account has been established as set forth in Section 2.01 and each Account will be maintained in the manner set forth herein until termination of this Agreement.  The Securities Intermediary shall not change the name or account number of any Account without the prior written consent of the Secured Party.  The Securities Intermediary is acting hereunder in the capacity of a “securities intermediary” within the meaning of Section 8-102(a)(14) of the UCC.

(b)            No financial asset carried in an Account is or will be registered in the name of the Issuer, payable to the order of the Issuer, or specially endorsed to the Issuer, except to the extent that such financial asset has been endorsed to the Securities Intermediary or in blank.

(c)            This Agreement is the valid and legally binding obligation of the Securities Intermediary.

(d)            The Securities Intermediary has not entered into, and until the termination of this Agreement will not enter into, any agreement pursuant to which it agrees to comply with Entitlement Orders of any Person other than the Secured Party or the Issuer, in each case to the extent provided in Section 2.03, with respect to the Accounts.

(e)            The Securities Intermediary has not entered into any other agreement with the Secured Party or the Issuer purporting to limit or condition the obligation of the Securities Intermediary to comply with Entitlement Orders as set forth in Section 2.03.

(f)            The Securities Intermediary has at the time of this Agreement and shall continuously maintain have a place of business in the United States at which any of the activities of the Securities Intermediary are carried on and which (i) alone or together with other offices of the Securities Intermediary or with other persons acting for the Securities Intermediary in the United States or another nation (A) effects or monitors entries to securities accounts, (B) administers payments or corporate actions relating to securities held with the Securities Intermediary or such other persons, or (C) is otherwise engaged in a business or other regular activity of maintaining securities accounts ; or (ii)  is identified by an account number, bank code, or other specific means of identification as maintaining securities accounts in the United States.

4

ARTICLE FOUR

 MISCELLANEOUS

Section 4.01.        Choice of Law.  This Agreement and the Accounts shall be governed by the laws of the State of New York.  Regardless of any provision in any other agreement, for purposes of the UCC, New York shall be deemed to be the Securities Intermediary’s jurisdiction and the Accounts (as well as the Security Entitlements related thereto) shall be governed by the laws of the State of New York, and the law of the State of New York shall govern all issues specified in Article 2(1) of the Hague Securities Convention.  The parties will not agree to any amendment to this Agreement or the Indenture to change the governing law to any law other than the laws of the State of New York.

Section 4.02.        Conflict with other Agreements.  There are no agreements (other than this Agreement and the Indenture) entered into between the Securities Intermediary in such capacity and the Issuer with respect to the Accounts.  In the event of any conflict between this Agreement (or any portion thereof) and any other agreement now existing or hereafter entered into, the terms of this Agreement shall prevail.

Section 4.03.        Amendments.  No amendment or modification of this Agreement or waiver of any right hereunder shall be binding on any party hereto unless it is in writing and is signed by all of the parties hereto.

Section 4.04.        Successors.  The terms of this Agreement shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective corporate successors.

Section 4.05.        Notices.  All demands, notices and communications hereunder shall be in writing and shall be deemed to have been duly given if personally delivered at or mailed by registered mail, return receipt requested, to, in the case of (i) the Issuer, at c/o Wilmington Trust, National Association, Rodney Square North, 1100 North Market Street, Wilmington, DE 19890, Attention: Corporate Trust Administration, with a copy to BMW Financial Services NA, LLC, as Administrator, at 300 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (telecopier no. (201) 307-9286), Attention: General Counsel; (ii) the Indenture Trustee and the Secured Party, at 190 South LaSalle Street, 7th Floor, Chicago, Illinois 60603, Attention: Global Structured Finance/BMW Vehicle Lease Trust 2017-2; and (iii) the Securities Intermediary, at 190 South LaSalle Street, 7th Floor, Chicago, Illinois 60603, Attention: Global Structured Finance/BMW Vehicle Lease Trust 2017-2; or as to any of such parties, at such other address as shall be designated by such party in a written notice to the other parties.

Section 4.06.        Termination.  The rights and powers granted herein to the Secured Party have been granted in order to perfect its security interest in the Accounts, are powers coupled with an interest and will neither be affected by the bankruptcy of the Issuer or the lapse of time.  The obligations of the Securities Intermediary hereunder shall continue in effect with respect to the Accounts until the Secured Party has notified the Securities Intermediary in writing that its security interests under the Indenture have been terminated.

5

Section 4.07.        Counterparts.  This Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Agreement by signing and delivering one or more counterparts.

Section 4.08.        Limitation of Liability of Owner Trustee.  The parties hereto are put on notice and hereby acknowledge and agree that (a) this Agreement is executed and delivered by Wilmington Trust, National Association, not individually or personally but solely as Owner Trustee of the Issuer, in the exercise of the powers and authority conferred and vested in it, (b) each of the representations, undertakings and agreements herein made on the part of the Issuer is made and intended not as personal representations, undertakings and agreements by Wilmington Trust, National Association but is made and intended for the purpose of binding only the Issuer, (c) nothing herein contained shall be construed as creating any liability on Wilmington Trust, National Association, individually or personally, to perform any covenant either expressed or implied contained herein of the Issuer, all such liability, if any, being expressly waived by the parties hereto and by any Person claiming by, through or under the parties hereto, (d) Wilmington Trust, National Association has made no investigation as to the accuracy or completeness of any representations and warranties made by the Issuer in this Agreement and (e) under no circumstances shall Wilmington Trust, National Association be personally liable for the payment of any indebtedness or expenses of the Issuer or be liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken by the Issuer under this Agreement or any other related documents.

Section 4.09.        Communications with Rating Agencies.   If the Securities Intermediary shall receive any written or oral communication from any Rating Agency (or any of their respective officers, directors or employees) with respect to the transactions contemplated hereby or under the Basic Documents or in any way relating to the Notes, such party agrees to refrain from communicating with such Rating Agency and to promptly (and, in any event, within one Business Day) notify the Administrator of such communication.  Each of the Indenture Trustee and the Securities Intermediary agree to act at the direction of the Administrator with respect to any communication to a Rating Agency and further agree that in no event shall such party engage in any oral communication with respect to the transactions contemplated hereby or under the Basic Documents or in any way relating to the Notes with any Rating Agency (or any of their respective officers, directors or employees) without the participation of the Administrator.

[SIGNATURE PAGE FOLLOWS]

6

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective officers as of the day and year first above written.

BMW VEHICLE LEASE TRUST 2017-2,

as Issuer

		By:	
Wilmington Trust, National Association, not in its individual capacity but solely as Owner Trustee

By:    /s/ Clarice Wright                                             

      Name:   Clarice Wright

      Title:     Assistant Vice President

U.S. BANK NATIONAL ASSOCIATION,

not in its individual capacity but solely as Indenture Trustee and as Secured Party

By:   /s/ Jose A. Galarza                                          

      Name:   Jose A. Galarza

      Title:     Vice President

 

 

U.S. BANK NATIONAL ASSOCIATION,

 as Securities Intermediary

 

 

By:  /s/ Jose A. Galarza                                           

      Name:   Jose A. Galarza

      Title:   Vice PresidentEXECUTION
COPY

 

CLINICAL
TRIAL COLLABORATION AND SUPPLY AGREEMENT

 

by
and among

 

MSD
International GmbH

 

and

 

OncoSec
Medical Incorporated

 

Dated:
May 10, 2017

 

    	 

    	 

    

 

TABLE
OF CONTENTS

	 	 	 	Page
	1	Definitions	1
	2	 Scope of the Agreement.	8
	 	2.1.	Generally	8
	 	2.2.	Manufacturing Delay.	8
	 	2.3.	Compound Commitments	8
	 	2.4.	Delegation of Obligations	9
	 	2.5.	Compounds	9
	3	Conduct of the Study	9
	 	3.1.	Sponsor	9
	 	3.2.	Performance	9
	 	3.3.	Debarred Personnel; Exclusions Lists	9
	 	3.4.	Regulatory Matters	10
	 	3.5.	Documentation	10
	 	3.6.	Copies	10
	 	3.7.	Sample Testing	10
	 	3.8.	Ownership and Use of Clinical Data	11
	 	3.9.	Regulatory Submission	11
	 	3.10.	Joint Development Committee; Alliance Managers	11
	 	3.11.	Final Study Report	12
	 	3.12.	Relationship	12
	 	3.13.	Licensing	12
	 	3.14.	Subsequent Study	13
	4	 Protocol and Informed Consent; Certain Covenants	13
	 	4.1.	Protocol.	13
	 	4.2.	Informed Consent.	14
	 	4.3.	Financial Disclosure	14
	 	4.4.	Transparency Reporting.	14
	5	 Adverse Event Reporting	15
	 	5.1.	Pharmacovigilance Agreement	15
	 	5.2.	Transmission of SAEs	15

 

    	 

    	 

    

 

	6	 Term and Termination.	15
	 	6.1.	Term	15
	 	6.2.	Merck Termination for Safety	15
	 	6.3.	Termination for Material Breach	16
	 	6.4.	Termination for Patient Safety	16
	 	6.5.	Termination for Regulatory Action; Other Reasons	16
	 	6.6.	Termination related to Anti-Corruption Obligations	16
	 	6.7.	Return of Merck Compound	16
	 	6.8.	Survival	16
	 	6.9.	No Prejudice	17
	 	6.10.	Confidential Information	17
	 	6.11.	Manufacturing Costs	17
	7	 Costs of Study	17
	8	 Supply and Use of the Compounds	17
	 	8.1.	Supply of the Compounds	17
	 	8.2.	Clinical Quality Agreement	18
	 	8.3.	Minimum Shelf Life Requirements	18
	 	8.4.	Provision of Compounds	18
	 	8.5.	Labeling and Packaging; Use, Handling and Storage	19
	 	8.6.	Product Specifications	19
	 	8.7.	Changes to Manufacturing	19
	 	8.8.	Product Testing; Noncompliance	19
	 	8.9.	Investigations	21
	 	8.10.	Shortage; Allocation	21
	 	8.11.	Records; Audit Rights	21
	 	8.12.	Quality	21
	 	8.13.	Quality Control	21
	 	8.14.	Audits and Inspections	21
	 	8.15.	Recalls	21
	 	8.16.	VAT	21
	9	 Confidentiality	22
	 	9.1.	Confidential Information	22
	 	9.2.	Inventions	22
	 	9.3.	Personal Identifiable Data	23

 

    	 

    	 

    

 

	10	 Intellectual Property	23
	 	10.1.	Joint Ownership and Prosecution	23
	 	10.2.	Inventions Owned by Company	24
	 	10.3.	Inventions Owned by Merck	24
	 	10.4.	Mutual Freedom to Operate for Combination Inventions	24
	11	 Reprints; Rights of Cross-Reference	25
	12	 Publications; Press Releases	25
	 	12.1.	Clinical Trial Registry	25
	 	12.2.	Publication	25
	 	12.3.	Press Releases	25
	13	 Representations and Warranties; Disclaimers	26
	 	13.1.	Due Authorization	26
	 	13.2.	Compounds	26
	 	13.3.	Results	26
	 	13.4.	Anti-Corruption	26
	 	13.5.	DISCLAIMER	28
	14	 Insurance; Indemnification; Limitation of Liability	28
	 	14.1.	Insurance	28
	 	14.2.	Indemnification	28
	 	14.3.	LIMITATION OF LIABILITY	29
	15	 Use of Name	30
	16	 Force Majeure	30
	17	 Entire Agreement; Amendment; Waiver	30
	18	 Assignment and Affiliates	30
	19	 Invalid Provision	30
	20	 No Additional Obligations	31
	21	 Governing Law; Dispute Resolution	31
	22	 Notices	31
	23	Relationship of the Parties	32
	24	 Counterparts and Due Execution	32
	25	

 Construction	32

 

	Appendices
	Appendix A – Protocol Synopsis
	Appendix B – Supply of Compound
	Appendix C – Company Press Release
	 
	Schedules
	Schedule I – Data Sharing and Sample Testing Schedule

 

    	 	ii	 

     

    

 

CLINICAL
TRIAL COLLABORATION AND SUPPLY AGREEMENT

 

This
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), is entered into as of May 10, 2017 (the
“Effective Date”), by and among MSD International GmbH, having a place of business at Weystrasse 20, 6000 Luzern
6, Switzerland (“Merck”), and OncoSec Medical Incorporated, having a place of business at 5820 Nancy Ridge
Drive, San Diego, California 92121 USA (“Company”). Merck and Company are each referred to herein individually
as “Party” and collectively as “Parties”.

 

RECITALS

 

A.
Merck holds intellectual property rights with respect to the Merck Compound (as defined below).

 

B.
Company is developing the Company Compound (as defined below) for the treatment of certain tumor types.

 

C.
Merck is developing the Merck Compound for the treatment of certain tumor types.

 

D.
Company desires to sponsor a clinical trial in which the Company Compound and the Merck Compound would be dosed concurrently or
in combination.

 

E.
Merck and Company, consistent with the terms of this Agreement, desire to collaborate as more fully described herein, including
by providing the Merck Compound and the Company Compound for the Study (as defined below).

 

NOW,
THEREFORE, in consideration of the premises and of the following mutual promises, covenants and conditions, the Parties, intending
to be legally bound, mutually agree as follows:

 

1.
Definitions.

 

For
all purposes of this Agreement, the capitalized terms defined in this Article 1 and throughout this Agreement shall have
the meanings herein specified.

 

1.1.
“Affiliate” means, with respect to either Party, a firm, corporation or other entity that, now or hereafter,
directly or indirectly owns or controls said Party, or, now or hereafter, is owned or controlled by said Party, or is under common
ownership or control with said Party. The word “control” as used in this definition means (a) the direct or
indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal entity or (b) possession, directly
or indirectly, of the power to direct the management or policies of a legal entity, whether through the ownership of voting securities,
contract rights, voting rights, corporate governance or otherwise.

 

1.2.
“Agreement” means this agreement, as amended by the Parties from time to time, and as set forth in the preamble.

 

1.3.
“Alliance Manager” has the meaning set forth in Section 3.10.3.

 

    	 	1	 

     

    

 

1.4.
“Applicable Law” means all federal, state, local, national and regional statutes, laws, rules, regulations
and directives applicable to a particular activity hereunder, including performance of clinical trials, medical treatment and
the processing and protection of personal and medical data, that may be in effect from time to time, including those promulgated
by the United States Food and Drug Administration (“FDA”), national regulatory authorities, the European Medicines
Agency (“EMA”) and any successor agency to the FDA or EMA or any agency or authority performing some or all
of the functions of the FDA or EMA in any jurisdiction outside the United States or the European Union (each a “Regulatory
Authority” and collectively, “Regulatory Authorities”), and including cGMP and GCP (each as defined
below); all data protection requirements such as those specified in the EU Data Protection Directive and the regulations issued
under the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”); export control
and economic sanctions regulations which prohibit the shipment of United States-origin products and technology to certain restricted
countries, entities and individuals; anti-bribery and anti-corruption laws pertaining to interactions with government agents,
officials and representatives; laws and regulations governing payments to healthcare providers; and any United States or other
country’s or jurisdiction’s successor or replacement statutes, laws, rules, regulations and directives relating to
the foregoing.

 

1.5.
“Business Day” means any day other than a Saturday, Sunday, or a day on which commercial banks located in the
country where the applicable obligations are to be performed are authorized or required by law to be closed.

 

1.6.
“cGMP” means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA and
other applicable Regulatory Authorities that may be in effect from time to time and are applicable to the Manufacture of the Compounds.

 

1.7.
“Clinical Data” means all data (including raw data) and results generated by or on behalf of either Party or
at either Party’s direction, or by or on behalf of the Parties together or at their direction, in the course of each such
Party’s performance of the Study; provided however, that Clinical Data does not include Sample Testing Results.

 

1.8.
“Clinical Quality Agreement” has the meaning set forth in Section 8.2.

 

1.9.
“CMC” means “Chemistry Manufacturing and Controls” as such term of art is used in the pharmaceutical
industry.

 

1.10.
“Combination” means the use or method of using the Company Compound and the Merck Compound in concomitant or
sequential administration.

 

1.11.
“Company” has the meaning set forth in the preamble.

 

1.12.
“Company Background Patents” has the meaning set forth in Section 10.4.1.

 

1.13.
“Company Class Compound” means any intratumorally-delivered plasmid containing a DNA sequence that encodes
interleukin 12 (IL-12).

 

1.14.
“Company Compound” means intratumoral plasmid interleukin 12 (pIL-12) with electroporation (IT-pIL-12-EP),
excluding, however, any biosimilar version of intratumoral plasmid interleukin 12 (pIL-12) with electroporation (IT-pIL 12-EP)
other than a biosimilar version Controlled by Company or its Affiliate.

 

    	 	2	 

     

    

 

1.15.
“Company Inventions” has the meaning set forth in Section 10.2.

 

1.16.
“Compounds” means the Company Compound and the Merck Compound. A “Compound” means either
the Company Compound or the Merck Compound, as applicable.

 

1.17.
“Confidential Information” means any information, Know-How or other proprietary information or materials furnished
to one Party (“Receiving Party”) by or on behalf of the other Party (“Disclosing Party”)
in connection with this Agreement, except to the extent that such information or materials: (a) was already known to the Receiving
Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party, as demonstrated by
competent evidence; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure
to the Receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure
and other than through any act or omission of the Receiving Party in breach of this Agreement; (d) was disclosed to the Receiving
Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or (e) was subsequently
developed by the Receiving Party without use of the Disclosing Party Confidential Information, as demonstrated by competent evidence.

 

1.18.
“Continuing Party” has the meaning set forth in Section 10.1.3.

 

1.19.
“Control” or “Controlled” means, with respect to particular information or intellectual
property, that the applicable Party owns or has a license to such information or intellectual property and has the ability to
grant a right, license or sublicense to the other Party as provided for herein without violating the terms of any agreement or
other arrangement with any Third Party.

 

1.20.
“CTA” means an application to a Regulatory Authority for purposes of requesting the ability to start or continue
a clinical trial.

 

1.21.
“Data Sharing and Sample Testing Schedule” means the schedule attached hereto as Schedule I.

 

1.22.
“Defending Party” has the meaning set forth in Section 14.2.3.

 

1.23.
“Delivery” with respect to the Merck Compound has the meaning set forth in Section 8.4.1, and with respect
to the Company Compound, the meaning set forth in Section 8.4.2.

 

1.24.
“Direct Manufacturing Costs” has the meaning set forth in Section 6.11.

 

1.25.
“Disclosing Party” has the meaning set forth in the definition of Confidential Information in Section 1.17.

 

1.26.
“Disposition Package” has the meaning set forth in Section 8.8.1.

 

    	 	3	 

     

    

 

1.27.
“Effective Date” has the meaning set forth in the preamble.

 

1.28.
“EMA” has the meaning set forth in the definition of Applicable Law in Section 1.4.

 

1.29.
“Exclusions List” has the meaning set forth in the definition of Violation in Section 1.84.

 

1.30.
“FDA” has the meaning set forth in the definition of Applicable Law in Section 1.4.

 

1.31.
“Filing Party” has the meaning set forth in Section 10.1.3.

 

1.32.
“Final Study Report” has the meaning set forth in Section 3.11.

 

1.33.
“Force Majeure” has the meaning set forth Article 16.

 

1.34.
“GAAP” has the meaning set forth in Section 6.11.

 

1.35.
“GCP” means the Good Clinical Practices officially published by EMA, FDA and the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) that may be in effect from time
to time and are applicable to the testing of the Compounds.

 

1.36.
“Government Official” means: (a) any officer or employee of a government or any department, agency or instrument
of a government; (b) any Person acting in an official capacity for or on behalf of a government or any department, agency, or
instrument of a government; (c) any officer or employee of a company or business owned in whole or part by a government; (d) any
officer or employee of a public international organization such as the World Bank or United Nations; (e) any officer or employee
of a political party or any Person acting in an official capacity on behalf of a political party; and/or (f) any candidate for
political office; who, when such Government Official is acting in an official capacity, or in an official decision-making role,
has responsibility for performing regulatory inspections, government authorizations or licenses, or otherwise has the capacity
to make decisions with the potential to affect the business of either of the Parties.

 

1.37.
“HIPAA” has the meaning set forth in the definition of Applicable Law in Section 1.4.

 

1.38.
“IND” means any Investigational New Drug Application filed or to be filed with the FDA as described in Title
21 of the U.S. Code of Federal Regulations, Part 312, and the equivalent application in the jurisdictions outside the United States,
including an “Investigational Medicinal Product Dossier” filed or to be filed with Regulatory Authorities in the European
Union.

 

1.39.
“Indirect Manufacturing Costs” has the meaning set forth in Section 6.11.

 

    	 	4	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

1.40.
“Inventions” means all inventions and discoveries, whether or not patentable, that are made, conceived, or
first actually reduced to practice by or on behalf of a Party, or by or on behalf of the Parties together, (a) in the design or
performance of the Study or (b) through use of unpublished Clinical Data.

 

1.41.
“Joint Development Committee” or “JDC” has the meaning set forth in Section 3.10.1.

 

1.42.
“Joint Patent Application” has the meaning set forth in Section 10.1.3.

 

1.43.
“Joint Patent” means a patent that issues from a Joint Patent Application.

 

1.44.
“Jointly Owned Invention” has the meaning set forth in Section 10.1.1.

 

1.45.
“Know-How” means any proprietary invention, innovation, improvement, development, discovery, computer program,
device, trade secret, method, know-how, process, technique or the like, including manufacturing, use, process, structural, operational
and other data and information, whether or not written or otherwise fixed in any form or medium, regardless of the media on which
contained and whether or not patentable or copyrightable, that is not generally known or otherwise in the public domain.

 

1.46.
“Liability” has the meaning set forth in Section 14.2.1.

 

1.47.
“Manufacture,” “Manufactured,” or “Manufacturing” means all activities
related to the manufacture of a Compound, including planning, purchasing, manufacture, processing, compounding, storage, filling,
packaging, waste disposal, labeling, leafleting, testing, quality assurance, sample retention, stability testing, release, dispatch
and supply, as applicable.

 

1.48.
“Manufacturer’s Release” or “Release” has the meaning ascribed to such term in the
Clinical Quality Agreement.

 

1.49.
“Manufacturing Site” means the facilities where a Compound is Manufactured by or on behalf of a Party, as such
Manufacturing Site may change from time to time in accordance with Section 8.7.

 

1.50.
“Merck” has the meaning set forth in the preamble.

 

1.51.
“Merck Background Patents” has the meaning set forth in Section 10.4.2.

 

1.52.
“Merck Compound” means pembrolizumab, a humanized anti-human PD-1 monoclonal antibody[*****].

 

1.53.
“Merck Inventions” has the meaning set forth in Section 10.3.

 

1.54.
“NDA” means a New Drug Application, Biologics License Application, Marketing Authorization Application, filing
pursuant to Section 510(k) of the United States Federal Food, Drug and Cosmetic Act, or similar application or submission for
a marketing authorization of a product filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical
or diagnostic product in that country or in that group of countries.

 

    	 	5	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

1.55.
“Non-Conformance” means, with respect to a given unit of Compound, (a) an event that deviates from an approved
cGMP requirement with respect to the applicable Compound, such as a procedure, Specification, or operating parameter, or that
requires an investigation to assess impact to the quality of the applicable Compound or (b) that such Compound failed to meet
the applicable representations and warranties set forth in Section 2.3. Classification of the Non-Conformance is detailed
in the Clinical Quality Agreement.

 

1.56.
“Non-Filing Party” has the meaning set forth in Section 10.1.3.

 

1.57.
“Other Party” has the meaning set forth in Section 14.2.3.

 

1.58.
“Opting-out Party” has the meaning set forth in Section 10.1.3.

 

1.59.
“Party” has the meaning set forth in the preamble.

 

1.60.
“PD-1 Antagonist” means any small or large molecule that [*****].

 

1.61.
“Person” means any individual, sole proprietorship, partnership, corporation, business trust, joint stock company,
trust, unincorporated organization, association, limited liability company, institution, public benefit corporation, joint venture,
entity or governmental entity.

 

1.62.
“Pharmacovigilance Agreement” has the meaning set forth in Section 5.1.

 

1.63.
“Project Manager” has the meaning set forth in Section 3.10.1.

 

1.64.
“Protocol” means the written documentation that describes the Study and sets forth specific activities to be
performed as part of the conduct of the Study.

 

1.65.
“Receiving Party” has the meaning set forth in the definition of Confidential Information.

 

1.66.
“Regulatory Approvals” means, with respect to a Compound, any and all permissions (other than the Manufacturing
approvals) required to be obtained from Regulatory Authorities and any other competent authority for the development, registration,
importation and distribution of such Compound in the United States, Europe or other applicable jurisdictions for use in the Study.

 

1.67.
“Regulatory Authorities” has the meaning set forth in the definition of Applicable Law in Section 1.4.

 

1.68.
“Regulatory Documentation” means, with respect to the Compounds, all submissions to Regulatory Authorities
in connection with the development of such Compounds, including all INDs and amendments thereto, NDAs and amendments thereto,
drug master files, correspondence with regulatory agencies, periodic safety update reports, adverse event files, complaint files,
inspection reports and manufacturing records, in each case together with all supporting documents (including documents that include
Clinical Data).

 

    	 	6	 

     

    

 

1.69.
“Related Agreements” means the Pharmacovigilance Agreement and the Clinical Quality Agreement.

 

1.70.
“Right of Reference” means the “right of reference” defined in 21 CFR 314.3(b), including with
regard to a Party, allowing the applicable Regulatory Authority in a country to have access to relevant information (by cross-reference,
incorporation by reference or otherwise) contained in Regulatory Documentation (and any data contained therein) filed with such
Regulatory Authority with respect to a Party’s Compound, only to the extent necessary for the conduct of the Study in such
country or as otherwise expressly permitted or required under this Agreement to enable a Party to exercise its rights or perform
its obligations hereunder.

 

1.71.
“SAEs” has the meaning set forth in Section 5.2.

 

1.72.
“Samples” means biological specimens collected from subjects participating in the Study, including urine, blood
and tissue samples.

 

1.73.
“Sample Testing” means the analyses to be performed by each Party using the applicable Samples, as described
in the Data Sharing and Sample Testing Schedule.

 

1.74.
“Sample Testing Results” means those data and results arising from the Sample Testing performed by a Party.

 

1.75.
“Specifications” means, with respect to a given Compound, the set of requirements for such Compound as set
forth in the Clinical Quality Agreement.

 

1.76.
“Study” means the multicenter, phase II, adaptive, open-label clinical trial to evaluate the safety and preliminary
efficacy of the concomitant and/or sequenced administration of the Merck Compound and the Company Compound in patients with Stage
III/IV Melanoma who are progressing on either the Merck Compound or nivolumab treatment.

 

1.77.
“Study Completion” has the meaning set forth in Section 3.11.

 

1.78.
“Subcontractors” has the meaning set forth in Section 2.4.

 

1.79.
“Subsequent Study” has the meaning set forth in Section 3.14.1.

 

1.80.
“Term” has the meaning set forth in Section 6.1.

 

1.81.
“Third Party” means any Person or entity other than Company, Merck or their respective Affiliates.

 

1.82.
“Toxicity & Safety Data” means all clinical adverse event information and/or patient-related safety data
included in the Clinical Data, as more fully described in the Pharmacovigilance Agreement.

 

    	 	7	 

     

    

 

1.83.
“VAT” has the meaning set forth in Section 8.16.

 

1.84.
“Violation” means that a Party or any of its officers or directors or any other personnel (or other permitted
agents of a Party performing activities hereunder) has been: (a) convicted of any of the felonies identified among the exclusion
authorities listed on the U.S. Department of Health and Human Services, Office of Inspector General (OIG) website, including 42
U.S.C. 1320a-7(a) (http://oig.hhs.gov/exclusions/authorities.asp); (b) identified in the OIG List of Excluded Individuals/Entities
(LEIE) database (http://exclusions.oig.hhs.gov/) or listed as having an active exclusion in the System for Award Management (http://www.sam.gov);
or (c) listed by any US Federal agency as being suspended, proposed for debarment, debarred, excluded or otherwise ineligible
to participate in Federal procurement or non-procurement programs, including under 21 U.S.C. 335a (http://www.fda.gov/ora/compliance_ref/debar/)
((a), (b) and (c) collectively the “Exclusions Lists”).

 

2.
Scope of the Agreement.

 

2.1.
Generally. Each Party shall: (a) contribute to the Study such resources as are necessary to fulfill its obligations
set forth in this Agreement; and (b) act in good faith in performing its obligations under this Agreement and each Related Agreement
to which it is a Party.

 

2.2.
Manufacturing Delay. Each Party shall notify the other Party as promptly as possible in the event of any Manufacturing
delay that is likely to adversely affect supply of its Compound as contemplated by this Agreement.

 

2.3.
Compound Commitments.

 

2.3.1.
Company agrees to Manufacture and supply the Company Compound for purposes of the Study in accordance with Article 8, and
Company hereby represents and warrants to Merck that, at the time of Delivery of the Company Compound, such Company Compound shall
have been Manufactured and supplied in compliance with: (a) the Specifications for the Company Compound; (b) the Clinical Quality
Agreement; and (c) all Applicable Law, including cGMP and health, safety and environmental protections.

 

2.3.2.
Merck agrees to Manufacture and supply the Merck Compound for purposes of the Study in accordance with Article 8, and Merck
hereby represents and warrants to Company that, at the time of Delivery of the Merck Compound, such Merck Compound shall have
been Manufactured and supplied in compliance with: (a) the Specifications for the Merck Compound; (b) the Clinical Quality Agreement;
and (c) all Applicable Law, including cGMP and health, safety and environmental protections.

 

2.3.3.
Without limiting the foregoing, each Party is responsible for obtaining all regulatory approvals (including facility licenses)
that are required to Manufacture its Compound in accordance with Applicable Law (provided that, for clarity, Company shall
be responsible for obtaining Regulatory Approvals for the Study as set forth in Section 3.4).

 

    	 	8	 

     

    

 

2.4.
Delegation of Obligations. Each Party shall have the right to delegate any portion of its obligations hereunder
as follows: (a) to such Party’s Affiliates; (b) to Third Parties that are set forth in the Protocol as performing Study
activities or as conducting Sample Testing for such Party; (c) to the extent related to the Manufacture of such Party’s
Compound; and (d) upon the other Party’s prior written consent. Any and all Third Parties to whom a Party delegates any
of its obligations hereunder are referred to as “Subcontractors”. Notwithstanding any delegation of its obligations
hereunder, each Party shall remain solely and fully liable for the performance of its Affiliates and Subcontractors to which such
Party delegates the performance of its obligations under this Agreement. Each Party shall ensure that each of its Affiliates and
Subcontractors performs such Party’s obligations pursuant to the terms of this Agreement, including the Appendices and Schedules
attached hereto. Each Party shall use reasonable efforts to obtain and maintain copies of documents relating to the obligations
performed by such Affiliates and Subcontractors that are required to be provided to the other Party under this Agreement.

 

2.5.
Compounds. This Agreement does not create any obligation on the part of Merck to provide the Merck Compound for
any activities other than the Study, nor does it create any obligation on the part of Company to provide the Company Compound
for any activities other than the Study.

 

3.
Conduct of the Study.

 

3.1.
Sponsor. Company shall act as the sponsor of the Study under its existing IND for the Company Compound with a Right
of Reference to the IND of the Merck Compound, as necessary, as further described in Section 3.4; provided, however,
that in no event shall Company file an additional IND for the Study unless required by Regulatory Authorities to do so. If a Regulatory
Authority requests an additional IND for the Study the Parties shall meet and mutually agree on an approach to address such requirement.

 

3.2.
Performance. Company shall ensure that the Study is performed in accordance with this Agreement, the Protocol and
all Applicable Law, including GCP.

 

3.3.
Debarred Personnel; Exclusions Lists. Notwithstanding anything to the contrary contained herein, Company shall not
employ or subcontract with any Person that is excluded, debarred, suspended, proposed for suspension or debarment, in Violation
or otherwise ineligible for government programs for the performance of the Study or any other activities under this Agreement
or the Related Agreements. Company hereby certifies that it has not employed or otherwise used in any capacity and will not employ
or otherwise use in any capacity, the services of any Person suspended, proposed for debarment, or debarred under United States
law, including 21 USC 335a, or any foreign equivalent thereof, in performing any portion of the Study or other activities under
this Agreement or the Related Agreements and that Company has, as of the Effective Date, screened itself, and its officers and
directors, against the Exclusions Lists and that it has informed Merck whether it or any of its officers or directors has been
in Violation. Company shall notify Merck in writing immediately if any such suspension, proposed debarment, debarment or Violation
occurs or comes to its attention, and shall, with respect to any Person so suspended, proposed for debarment, debarred or in Violation,
promptly remove such Person from performing in any capacity related to the Study or otherwise related to activities under this
Agreement or the Related Agreements.

 

    	 	9	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

3.4.
Regulatory Matters. Company shall: (a) obtain, prior to initiating the Study, all Regulatory Approvals from all Regulatory
Authorities, ethics committees and/or institutional review boards with jurisdiction over the Study prior to initiating the Study;
and (b) follow all directions from any such Regulatory Authorities, ethics committees and/or institutional review boards. Merck
shall have the right (but not the obligation) to participate in any discussions with a Regulatory Authority regarding matters
related to the Merck Compound. If a Right of Reference is necessary, each Party shall provide to the other a cross-reference letter
or similar communication to the applicable Regulatory Authority if needed to effectuate the Right of Reference. Notwithstanding
anything to the contrary in this Agreement, neither Party shall have any right to access the other Party’s CMC data with
respect to such other Party’s Compound. Merck shall authorize FDA and other applicable Regulatory Authorities to cross-reference
the appropriate Merck Compound INDs and CTAs to provide data access to Company sufficient to support conduct of the Study. If
Merck’s CTA is not available in a given country, Merck will file its CMC data with the Regulatory Authority for such country,
referencing Company’s CTA as appropriate ([*****]).

 

3.5.
Documentation. Company shall maintain reports and all related documentation in good scientific manner and in compliance
with Applicable Law. Company shall provide to Merck all Study information and documentation reasonably requested by Merck to enable
Merck to (a) comply with any of its legal, regulatory and/or contractual obligations, or any request by any Regulatory Authority,
related to the Merck Compound and (b) determine whether the Study has been performed in accordance with this Agreement.

 

3.6.
Copies. Company shall provide to Merck copies of all Clinical Data, in electronic form or other mutually agreeable
alternate form and on the timelines specified in the Data Sharing and Sample Testing Schedule (if applicable) or upon mutually
agreeable timelines; provided, however, that a complete copy of the Clinical Data shall be provided to Merck no
later than forty-five (45) days following Study Completion. Company shall ensure that all patient authorizations and consents
required under HIPAA, the EU Data Protection Directive or any other similar Applicable Law in connection with the Study permit
such sharing of Clinical Data with Merck.

 

3.7.
Sample Testing.

 

3.7.1.
Company shall provide Samples to Merck as specified in the Protocol or as agreed to by the Joint Development Committee. Each Party
shall (a) use the Samples only for the Sample Testing and (b) conduct the Sample Testing solely in accordance with the Data Sharing
and Sample Testing Schedule and the Protocol.

 

3.7.2.
Merck shall own all Sample Testing Results arising from Sample Testing performed by or on behalf of Merck. Solely to the extent
specified on the Data Sharing and Sample Testing Schedule as being shared, Merck shall provide to Company the Sample Testing Results
for the Sample Testing conducted by or on behalf of Merck, in electronic form or other mutually agreeable alternate form, on the
timelines specified in the Data Sharing and Sample Testing Schedule or as otherwise mutually agreed.

 

    	 	10	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

3.7.3.
Company shall own all Sample Testing Results arising from Sample Testing performed by or on behalf of Company. Solely to the extent
specified on the Data Sharing and Sample Testing Schedule as being shared, Company shall provide to Merck the Sample Testing Results
for the Sample Testing conducted by or on behalf of Company, in electronic form or other mutually agreeable alternate form, on
the timelines specified in the Data Sharing and Sample Testing Schedule or as otherwise mutually agreed.

 

3.7.4.
Except to the extent otherwise agreed in a writing signed by authorized representatives of each Party, each Party may use and
disclose the Sample Testing Results owned by the other Party and shared by such other Party in accordance with the Data Sharing
and Sample Testing Schedule solely for the purposes of [*****].

 

3.8.
Ownership and Use of Clinical Data.

 

3.8.1.
[*****] Company shall maintain the Clinical Data in its internal database; provided, however, that at all times during
the Term, Company shall grant Merck access to all Clinical Data.

 

3.8.2.
Notwithstanding the foregoing, before publication of the Clinical Data in accordance with Article 12[*****]; provided,
however, that the foregoing shall not limit or restrict either Party’s ability to (i) use or disclose the Clinical
Data as may be necessary to comply with Applicable Law or with such Party’s internal policies and procedures with respect
to pharmacovigilance and adverse event reporting or (ii) share with Third Parties or Affiliates Toxicity and Safety Data where
because of severity, frequency or lack of reversibility either Party needs to use such Toxicity and Safety Data with respect to
its own Compound or the Combination to ensure patient safety.

 

3.9.
Regulatory Submission. It is understood and acknowledged by the Parties that positive Clinical Data could be used
to obtain label changes for the Compounds, and each Party may propose a Subsequent Study (as defined below) in connection therewith
in accordance with Section 3.14.

 

3.10.
Joint Development Committee; Alliance Managers.

 

3.10.1.
The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”)
made up of an equal number of representatives of Merck and Company, which shall have responsibility for coordinating all regulatory
and other activities under, and pursuant to, this Agreement. The JDC will review and finalize the Protocol in accordance with
Section 4.1. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible
for implementing and coordinating activities and facilitating the exchange of information between the Parties with respect to
the Study and shall be a member of the JDC. Other JDC members will be agreed by both Parties.

 

3.10.2.       The
JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably
considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person
or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such
meeting, Company’s Project Manager shall provide an update in writing to Merck’s Project Manager, which update shall
contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final
analysis and other information relevant to the conduct of the Study.

 

    	 	11	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

3.10.3.
In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”),
who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information
and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have
the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably
believes should be discussed and shall have such other responsibilities as the Parties may mutually agree in writing. In the event
that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, or if
there is a decision to be made by the JDC on which the members of the JDC cannot unanimously agree, the issue shall be elevated
to the Vice President of Clinical Oncology for Merck and the Chief Clinical and Regulatory Officer for Company. In the event such
escalation does not result in resolution or consensus: (a) Merck shall have final decision-making authority with respect to issues
related to Merck Compound; and (b) Company shall have final decision-making authority with respect to issues related to Company
Compound.

 

3.11.
Final Study Report. Company shall provide Merck with an electronic draft of the final study report promptly following
Study Completion, and Merck shall have [*****] days after receipt of such draft to provide comments thereon. Company shall consider
in good faith any comments provided by Merck on the draft final study report and shall not include any statements relating to
the Merck Compound that have not been approved by Merck. Company shall deliver to Merck a final version of the final study report
promptly following finalization thereof (the “Final Study Report”). “Study Completion” shall
occur upon database lock of the Study results.

 

3.12.
Relationship. Except as expressly set forth in this Agreement, nothing in this Agreement shall: (a) prohibit either
Party from performing clinical studies other than the Study relating to its own Compound, either individually or in combination
with any other compound or product, in any therapeutic area; or (b) create an exclusive relationship between the Parties with
respect to any Compound. Each Party acknowledges and agrees that nothing in this Agreement shall be construed as a representation
or inference that the other Party will not develop for itself, or enter into business relationships with other Third Parties regarding,
any products, programs, studies (including combination studies), technologies or processes that are similar to or that may compete
with the Combination or any other product, program, technology or process, including Company Class Compound or PD-1 Antagonists,
provided that the Clinical Data, Confidential Information, Jointly Owned Inventions and Sample Testing Results are not
used or disclosed in connection therewith in violation of this Agreement.

 

3.13.
Licensing. Nothing in this Agreement shall prohibit or restrict a Party from licensing, assigning or otherwise transferring
to an Affiliate or Third Party such Party’s Compound or any Inventions, Confidential Information or Sample Testing Results
owned solely by such Party. A Party may license, assign or transfer to an Affiliate or Third Party such Party’s interest
in the Clinical Data, Confidential Information owned jointly by the Parties and/or Jointly Owned Inventions, and in connection
therewith share the shared Sample Testing Results owned by the other Party, solely to the extent such licensee, assignee or transferee
agrees in writing to be bound by the terms of this Agreement with respect to such Clinical Data, Confidential Information, Jointly
Owned Inventions, and shared Sample Testing Results. For purposes of clarity, any assignment or transfer of this Agreement must
comply with Article 18 of this Agreement.

 

    	 	12	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

3.14.
Subsequent Study.

 

3.14.1
During the Term and for a period of [*****] months thereafter, either Party shall have the option to propose amending this Agreement
and the Related Agreements or negotiating a new agreement (a “Subsequent Study Agreement”), as appropriate,
for the purpose of conducting a registration study for the Combination in the same indication as the Study (each a “Subsequent
Study”) by sending a written proposal to the other Party. Company must offer Merck the option of participating in a
Subsequent Study prior to entering into an agreement with a Third Party to conduct a registration study in the same indication
and line of therapy as the Study of the Company Compound in concomitant and/or sequential administration with a PD-1 Antagonist.

 

3.14.2
If the receiving Party desires to engage in discussions around the proposed Subsequent Study, such Party shall notify the other
Party, in writing, no later than [*****] days after receipt of the written proposal. [*****]

 

4.
Protocol and Informed Consent; Certain Covenants.

 

4.1.
Protocol. A synopsis of
the initial Protocol and the draft statistical analysis plan for the Study have been agreed to by the Parties as of the Effective
Date and are attached hereto as Appendix A. Through the JDC, Company shall (a) provide a draft of the Protocol (and any subsequent
revisions thereof) to Merck for Merck’s review and comment, (b) consider in good faith any changes to the draft of the Protocol
requested by Merck, and (c) incorporate any changes requested by Merck with respect to Merck Compound. Company shall submit the
draft Protocol to the JDC for final approval, and the JDC shall promptly review the Protocol and vote on approval thereof. To
the extent the JDC cannot agree unanimously regarding the contents of the Protocol for final approval within [*****] days of receipt
of the Protocol: (i) Company shall have final decision-making authority with respect to matters in the Protocol related to the
Company Compound; (ii) Merck shall have final decision-making authority with respect to matters in the Protocol related to [*****];
and (iii) all other matters in respect of the Protocol on which the JDC cannot agree shall be resolved in accordance with Section
3.10.3. Once the final Protocol has been approved in accordance with this Section 4.1, any material changes to such approved final
Protocol (other than material changes relating solely to the Company Compound) and any changes to the final Protocol (whether
or not material) relating to the Merck Compound shall require Merck’s prior written consent. Any such proposed changes will
be sent in writing to Merck’s Project Manager and Merck’s Alliance Manager. Merck shall review promptly any such proposed
changes to the Protocol.

 

    	 	13	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

4.1.1.
Notwithstanding anything to the contrary contained herein, Merck, in its sole discretion, shall have the sole right to determine
the dose and dosing regimen for the Merck Compound and shall have the final decision on all matters relating to the Merck Compound
(including quantities of Merck Compound to be supplied pursuant to Article 8) and any information regarding the Merck Compound
included in the Protocol.

 

4.1.2.
Notwithstanding anything to the contrary contained herein, Company, in its sole discretion, shall have the sole right to determine
the dose and dosing regimen for the Company Compound and shall have the final decision on all matters relating to the Company
Compound (including quantities of Company Compound to be supplied pursuant to Article 8) and any information regarding
the Company Compound included in the Protocol.

 

4.2.
Informed Consent. Company shall prepare the patient informed consent form for the Study (which shall include provisions
regarding the use of Samples in Sample Testing) in consultation with Merck (it being understood and agreed that the portion of
the informed consent form relating to the Sample Testing of the Merck Compound shall be provided to Company by Merck). Any proposed
changes to such form that relate to the Merck Compound, including Sample Testing of the Merck Compound, shall be subject to Merck’s
prior written consent. Any such proposed changes will be sent in writing to Merck’s Project Manager and Merck’s Alliance
Manager. Merck will provide such consent, or a written explanation for why such consent is being withheld, within [*****] Business
Days after Merck receives a copy of Company’s requested changes.

 

4.3.
Financial Disclosure. Company shall (a) track and collect financial disclosure information from all “clinical
investigators” involved in the Study and (b) prepare and submit the certification and/or disclosure of the same in accordance
with all Applicable Law, including, but not limited to, Part 54 of Title 21 of the United States Code of Federal Regulations (Financial
Disclosure by Clinical Investigators) and related FDA Guidance Documents. Prior to the initiation of clinical activities under
the Study, but in any event within [*****] days after the Effective Date, the Parties shall determine whether Company shall track
and collect from all “clinical investigators” involved in the Study separate certification and/or disclosure forms
for each of Merck and Company or one (1) “combined” certification and/or disclosure form for both Merck and Company.
For purposes of this Section 4.3, the term “clinical investigators” shall have the meaning set forth in Part
54.2(d) of Title 21 of the United States Code of Federal Regulations.

 

4.4.
Transparency Reporting. Each Party shall be responsible for reporting payments and other transfers of value made
to health care professionals, including, without limitation, investigators, steering committee members, data monitoring committee
members, and consultants in connection with the Study in accordance with reporting requirements under Applicable Law, including,
without limitation, the Physician Payment Sunshine Act and state gift laws, and the European Federation of Pharmaceutical Industries
and Associations Disclosure Code, and such Party’s applicable policies; provided, however, if Company will not be
required to make a transparency report under Applicable Law for any annual reporting period thereunder, Company shall notify Merck
in writing of such status within [*****] calendar days after the commencement of such reporting period, and during such reporting
period the Company shall track and provide to Merck data regarding “indirect” payments or other transfers of value
by Company to such health care professionals to the extent such payments or other transfers of value were required, instructed,
directed or otherwise caused by Merck pursuant to this Agreement. The data will be in a format requested by Merck and provided
on a basis to be agreed upon by both Parties. Company represents and warrants that the information so provided will be complete
and accurate to the best of its knowledge.

 

    	 	14	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

5.
Adverse Event Reporting.

 

5.1.
Pharmacovigilance Agreement. Company will be solely responsible for compliance with all Applicable Laws pertaining
to safety reporting for the Study and related activities. The Parties (or their respective Affiliates) will execute a pharmacovigilance
agreement (the “Pharmacovigilance Agreement”) prior to the initiation of clinical activities under the Study,
but in any event within [*****] days after the Effective Date, to ensure the exchange of relevant safety data within appropriate
timeframes and in an appropriate format to enable the Parties to fulfill local and international regulatory reporting obligations
and to facilitate appropriate safety reviews. In the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance
Agreement, the terms of this Agreement shall control. The Pharmacovigilance Agreement will include safety data exchange procedures
governing the coordination of collection, investigation, reporting, and exchange of information concerning any adverse experiences,
pregnancy reports, and any other safety information arising from or related to the use of the Merck Compound and Company Compound
in the Study, consistent with Applicable Law. Such guidelines and procedures shall be in accordance with, and enable the Parties
and their Affiliates to fulfill, local and international regulatory reporting obligations to Government Authorities.

 

5.2.
Transmission of SAEs. Company will transmit to Merck all serious adverse events (“SAEs”) as follows:

 

5.2.1.
For drug-related fatal and life-threatening SAEs, Company will send a processed case (on a CIOMS-1 form in English) within [*****]
calendar days after receipt by Company of such SAEs.

 

5.2.2.
For all other SAEs, including non-drug-related fatal and life-threatening SAEs, Company will send a processed case (on a CIOMS-1
form in English) within [*****] calendar days after receipt by Company of such SAEs.

 

6.
Term and Termination.

 

6.1.
Term. The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect
until delivery of the Final Study Report, unless terminated earlier by either Party pursuant to this Article 6 (the “Term”).

 

6.2.
Merck Termination for Safety. In the event that Merck in good faith believes that the Merck Compound is being used
in the Study in an unsafe manner and notifies Company in writing of the grounds for such belief, and Company fails to promptly
incorporate changes into the Protocol requested by Merck to address such issue or to otherwise address such issue reasonably and
in good faith, Merck may terminate this Agreement and the supply of the Merck Compound immediately upon written notice to Company.

 

    	 	15	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

6.3.
Termination for Material Breach. Either Party may terminate this Agreement if the other Party commits a material
breach of this Agreement, and such material breach continues for [*****] days after receipt of written notice thereof from the
non-breaching Party; provided that if such material breach cannot reasonably be cured within [*****] days, the breaching
Party shall be given a reasonable period of time to cure such breach; provided further, that if such material breach is
incapable of cure, then the notifying Party may terminate this Agreement effective after the expiration of such [*****] day period.

 

6.4.
Termination for Patient Safety. If either Party determines in good faith, based on a review of the Clinical Data,
Sample Testing Results or other Study-related Know-How or other information, that the Study may unreasonably affect patient safety,
such Party shall promptly notify the other Party of such determination. The Party receiving such notice may propose modifications
to the Study to address the safety issue identified by the other Party and, if the notifying Party agrees, shall act to implement
immediately such modifications; provided, however, that if the notifying Party, in its sole discretion, believes
that there is imminent danger to patients, such Party need not wait for the other Party to propose modifications and may instead
terminate this Agreement immediately upon written notice to such other Party. Furthermore, if the notifying Party, in its sole
discretion, believes that any modifications proposed by the other Party will not resolve the patient safety issue, such Party
may terminate this Agreement effective upon written notice to such other Party.

 

6.5.
Termination for Regulatory Action; Other Reasons. Either Party may terminate this Agreement immediately upon written
notice to the other Party in the event that any Regulatory Authority takes any action, or raises any objection, that prevents
the terminating Party from supplying its Compound for purposes of the Study. Additionally, either Party shall have the right to
terminate this Agreement immediately upon written notice to the other Party in the event that it determines in its sole discretion
to withdraw any applicable Regulatory Approval for its Compound or to discontinue development of its Compound, for medical, scientific
or legal reasons.

 

6.6.
Termination related to Anti-Corruption Obligations. Either Party shall have the right to terminate this Agreement
immediately upon written notice to the other Party, if such other Party fails to perform any of its obligations under Section
13.4 or breaches any representation or warranty contained in Section 13.4. Except as set forth in Section 6.11,
the non-terminating Party shall have no claim against the terminating Party for compensation for any loss of whatever nature by
virtue of the termination of this Agreement in accordance with this Section 6.6.

 

6.7.
Return of Merck Compound. In the event that this Agreement is terminated, or in the event Company remains in possession
(including through any Affiliate or Subcontractor) of Merck Compound at the time this Agreement expires, Company shall, at Merck’s
sole discretion, promptly either return or destroy all unused Merck Compound pursuant to Merck’s instructions. If Merck
requests that Company destroy the unused Merck Compound, Company shall provide written certification of such destruction.

 

6.8.
Survival. The provisions of Sections 3.4 through 3.9 (inclusive), 3.14, 5, 6.7
through 6.11 (inclusive), 8.5.2, 8.11, 8.14 through 8.16 (inclusive), 12.2, 13.4.6,
14.2, and 14.3, and Articles 1, 5, 9 through 12 (inclusive), 17, and 20
through 25 (inclusive) shall survive the expiration or termination of this Agreement.

 

    	 	16	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

6.9.
No Prejudice. Termination of this Agreement shall be without prejudice to any claim or right of action of either
Party against the other Party for any prior breach of this Agreement.

 

6.10.
Confidential Information. Upon termination of this Agreement, each Party and its Affiliates shall promptly return
to the Disclosing Party or destroy any Confidential Information of the Disclosing Party (other than Clinical Data, Sample Testing
Results and Inventions) furnished to the Receiving Party by the Disclosing Party; provided, however that the Receiving
Party may retain one copy of such Confidential Information in its confidential files, solely for purposes of exercising the Receiving
Party’s rights hereunder, satisfying its obligations hereunder or complying with any legal proceeding or requirement with
respect thereto, and provided further that the Receiving Party shall not be required to erase electronic files created
in the ordinary course of business during automatic system back-up procedures pursuant to its electronic record retention and
destruction practices that apply to its own general electronic files and information so long as such electronic files are (a)
maintained only on centralized storage servers (and not on personal computers or devices), (b) not accessible by any of its personnel
(other than its information technology specialists), and (c) are not otherwise accessed subsequently except with the written consent
of the Disclosing Party or as required by law or legal process. Such retained copies of Confidential Information shall remain
subject to the confidentiality and non-use obligations herein.

 

6.11.
Manufacturing Costs. In the event of termination by Merck pursuant to Section 6.2, 6.3 or 6.6 above,
Merck shall be entitled to [*****] (as defined herein) incurred by Merck for its Compound Delivered for the Study. [*****]

 

7.
Costs of Study.

 

The
Parties agree that: (a) Merck shall provide the Merck Compound for use in the Study, as described in Article 8 below; (b)
each Party will be responsible for its own internal costs and expenses to support the Study and the costs of any Sample Testing
conducted by such Party in connection with the Study; and (c) Company shall bear all other costs associated with the conduct of
the Study, including that Company shall provide the Company Compound for use in the Study, as described in Article 8 below.
For the avoidance of doubt, Company will not be required to reimburse Merck for any costs or expenses incurred by Merck or its
Affiliates in connection with the Study (except as provided in Section 6.11) and Merck will not be required to reimburse
Company for any costs or expenses incurred by Company or its Affiliates in connection with the Study (except as provided in Section
6.11).

 

8.
Supply and Use of the Compounds.

 

8.1.
Supply of the Compounds. Subject to the terms and conditions of this Agreement, each of Company and Merck will use
commercially reasonable efforts to supply, or cause to be supplied, the quantities of its respective Compound as are set forth
in Appendix B, on the timelines set forth in Appendix B, in each case for use in the Study. If the Protocol is changed
in accordance with Article 4 in such a manner that may affect the quantities of Compound to be provided or the timing for
providing such quantities, the Parties shall amend Appendix B to reflect any changes required to be consistent with the
Protocol. Each Party shall also provide to the other Party a contact person for the supply of its Compound under this Agreement.
Notwithstanding the foregoing, or anything to the contrary herein, in the event that a Party is: (a) not supplying its Compound
in accordance with the terms of this Agreement, then the other Party shall have no obligation to supply its Compound; or (b) allocating
under Section 8.10 then the other Party may allocate proportionally.

 

    	 	17	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

8.2.
Clinical Quality Agreement. Within [*****] days after the Effective Date of this Agreement, but in any event before
any supply of Merck Compound hereunder, the Parties (or their respective Affiliates) shall enter into a quality agreement that
shall address and govern issues related to the quality of clinical drug supply to be supplied by the Parties for use in the Study
(the “Clinical Quality Agreement”). In the event of any inconsistency between the terms of this Agreement and
the Clinical Quality Agreement, the terms of this Agreement shall control. The Clinical Quality Agreement shall, among other things:
(a) detail classification of any Compound found to have a Non-Conformance; (b) include criteria for Manufacturer’s Release
and related certificates and documentation; (c) include criteria and timeframes for acceptance of Merck Compound; (d) include
procedures for the resolution of disputes regarding any Compounds found to have a Non-Conformance; and (e) include provisions
governing the recall of Compounds.

 

8.3.
Minimum Shelf Life Requirements. Each Party shall use commercially reasonable efforts to supply its Compound hereunder
with reasonable remaining shelf life at the time of Delivery to meet the Study requirements.

 

8.4.
Provision of Compounds.

 

8.4.1.
Merck will deliver the Merck Compound DAP (INCOTERMS 2010) to Company’s, or its designee’s, location as specified
by Company (“Delivery” with respect to such Merck Compound). Title and risk of loss for the Merck Compound
shall transfer from Merck to Company at Delivery. All costs associated with the subsequent transportation, warehousing and distribution
of Merck Compound shall be borne by Company. Company will, or will cause its designee to: (a) take delivery of the Merck Compound
supplied hereunder; (b) perform the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement;
(c) subsequently label and pack the Merck Compound (in accordance with Section 8.5); and promptly ship the Merck Compound
to the Study sites for use in the Study, in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement;
and (d) provide, from time to time at the reasonable request of Merck, the following information: any applicable chain of custody
forms, in-transport temperature recorder(s), records and receipt verification documentation, such other transport or storage documentation
as may be reasonably requested by Merck, and usage and inventory reconciliation documentation related to the Merck Compound.

 

8.4.2.
Company is solely responsible, at its own cost, for supplying (including all Manufacturing, acceptance and release testing) the
Company Compound for the Study, and the subsequent handling, storage, transportation, warehousing and distribution of the Company
Compound supplied hereunder. Company shall ensure that all such activities are conducted in compliance with cGMP, GCP and other
Applicable Law and the Clinical Quality Agreement. For purposes of this Agreement, the “Delivery” of a given
quantity of the Company Compound shall be deemed to occur when such quantity is packaged for shipment to a Study site.

 

    	 	18	 

     

    

 

8.5.
Labeling and Packaging; Use, Handling and Storage.

 

8.5.1.
The Parties’ obligations with respect to the labeling and packaging of the Compounds are as set forth in the Clinical Quality
Agreement. Notwithstanding the foregoing or anything to the contrary contained herein, Merck shall provide the Merck Compound
to Company in the form of unlabeled vials, and Company shall be responsible for labeling, packaging and leafleting such Merck
Compound in accordance with the terms and conditions of the Clinical Quality Agreement and otherwise in accordance with all Applicable
Law, including cGMP, GCP, and health, safety and environmental protections.

 

8.5.2.
Company shall: (a) use the Merck Compound solely for purposes of performing the Study; (b) not use the Merck Compound in any manner
that is inconsistent with this Agreement or for any commercial purpose; and (c) label, use, store, transport, handle and dispose
of the Merck Compound in compliance with Applicable Law and the Clinical Quality Agreement, as well as all written instructions
of Merck pertaining to the Merck Compound. Company shall not reverse engineer, reverse compile, disassemble or otherwise attempt
to derive the composition or underlying information, structure or ideas of the Merck Compound, and in particular shall not analyze
the Merck Compound by physical, chemical or biochemical means except as necessary to perform its obligations under the Clinical
Quality Agreement.

 

8.6.
Product Specifications. A certificate of analysis, Material Safety Data Sheet, and all storage and handling information
shall accompany each shipment of the Merck Compound to Company. Upon request, Company shall provide Merck with a certificate of
analysis covering each shipment of Company Compound used in the Study.

 

8.7.
Changes to Manufacturing. Each Party may make changes from time to time to its Compound or the Manufacturing Site,
provided that such changes shall be in accordance with the Clinical Quality Agreement.

 

8.8.
Product Testing; Noncompliance.

 

8.8.1.
After Manufacturer’s Release. After Manufacturer’s Release of the Merck Compound and concurrently with Delivery
of the Compound to Company, Merck shall provide Company with such certificates and documentation as are described in the Clinical
Quality Agreement (“Disposition Package”). Company shall, within the time defined in the Clinical Quality Agreement,
perform, with respect to the Merck Compound, the acceptance (including testing) procedures allocated to it under the Clinical
Quality Agreement. Company shall be solely responsible for taking all steps necessary to determine that Merck Compound or Company
Compound, as applicable, is suitable for release before making such Merck Compound or Company Compound, as applicable, available
for human use, and Merck shall provide cooperation or assistance as reasonably requested by Company in connection with such determination
with respect to the Merck Compound. Company shall be responsible for storage and maintenance of the Merck Compound until it is
tested and/or released, which storage and maintenance shall be in compliance with (a) the Specifications for the Merck Compound,
the Clinical Quality Agreement and Applicable Law and (b) any specific storage and maintenance requirements as may be provided
by Merck from time to time. Company shall be responsible for any failure of the Merck Compound to meet the Specifications to the
extent caused by shipping, storage or handling conditions after Delivery to Company hereunder.

 

    	 	19	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

8.8.2.
Non-Conformance.

 

(a)
In the event that either Party becomes aware that any Compound may have a Non-Conformance, despite testing and quality assurance
activities (including any activities conducted by the Parties under Section 8.8.1), such Party shall immediately notify
the other Party in accordance with the procedures of the Clinical Quality Agreement. The Parties shall investigate any Non-Conformance
in accordance with Section 8.9 (Investigations) and any discrepancy between them shall be resolved in accordance with Section
8.8.3.

 

(b)
In the event that any proposed or actual shipment of the Merck Compound (or portion thereof) shall be agreed to have a Non-Conformance
at the time of Delivery to Company, then unless otherwise agreed to by the Parties, Merck shall replace such Merck Compound as
is found to have a Non-Conformance (with respect to Merck Compound that has not yet been administered in the course of performing
the Study). Unless otherwise agreed to by the Parties in writing, the sole and exclusive remedies of Company with respect to any
Merck Compound that is found to have a Non-Conformance at the time of Delivery shall be (i) [*****], (ii)[*****] and (iii) [*****];
provided that, for clarity, Company shall not be deemed to be waiving any rights under Section 8.15. In the event
Merck Compound is lost or damaged by Company after Delivery, Merck shall provide additional Merck Compound (if available for the
Study) to Company; provided that Company shall [*****]. Except as set forth in the foregoing sentence, Merck shall have
no obligation to provide replacement Merck Compound for any Merck Compound supplied hereunder other than such Merck Compound as
has been agreed or determined to have a Non-Conformance at the time of Delivery to Company.

 

(c)
Company shall be responsible for, and Merck shall have no obligation or liability with respect to, any Company Compound supplied
hereunder that is found to have a Non-Conformance. Company shall replace any Company Compound as is found to have a Non-Conformance
(with respect to Company Compound that has not yet been administered in the course of performing the Study). Unless otherwise
agreed to by the Parties in writing, the sole and exclusive remedies of Merck with respect to any Company Compound that is found
to have a Non-Conformance at the time of Delivery shall be (i) [*****], (ii) [*****], and (iii) [*****]; provided
that, for clarity, Merck shall not be deemed to be waiving any rights under Section 8.15.

 

    	 	20	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

8.8.3.
Resolution of Discrepancies. Disagreements regarding any determination of Non-Conformance by Company shall be resolved
in accordance with the provisions of the Clinical Quality Agreement.

 

8.9.
Investigations. The process for investigations of any Non-Conformance shall be handled in accordance with the Clinical
Quality Agreement.

 

8.10.
Shortage; Allocation. In the event that a Party’s Compound is in short supply such that a Party reasonably
believes in good faith that it will not be able to fulfill its supply obligations hereunder with respect to its Compound, such
Party will provide prompt written notice to the other Party thereof (including the shipments of Compound hereunder expected to
be impacted and the quantity of its Compound that such Party reasonably determines it will be able to supply) and the Parties
will promptly discuss such situation (including how the quantity of Compound that such Party is able to supply hereunder will
be allocated within the Study). In such event, the Party experiencing such shortage shall (i) use its commercially reasonable
efforts to remedy the situation giving rise to such shortage and to take action to minimize the impact of the shortage on the
Study, and (ii) [*****].

 

8.11.
Records; Audit Rights. Company shall keep complete and accurate records pertaining to its use and disposition of
Merck Compound (including its storage, shipping (cold chain) and chain of custody activities) and, upon request of Merck, shall
make such records open to review by Merck for the purpose of conducting investigations for the determination of Merck Compound
safety and/or efficacy and Company’s compliance with this Agreement with respect to the Merck Compound.

 

8.12.
Quality. Quality matters related to the Manufacture of the Compounds shall be governed by the terms of the Clinical
Quality Agreement in addition to the relevant quality provisions of this Agreement.

 

8.13.
Quality Control. Each Party shall implement and perform operating procedures and controls for sampling, stability
and other testing of its Compound, and for validation, documentation and release of its Compound and such other quality assurance
and quality control procedures as are required by the Specifications, cGMPs and the Clinical Quality Agreement.

 

8.14.
Audits and Inspections. The Parties’ audit and inspection rights related to this Agreement shall be governed
by the terms of the Clinical Quality Agreement.

 

8.15.
Recalls. Recalls of the Compounds shall be governed by the terms of the Clinical Quality Agreement.

 

8.16.
VAT.

 

(a)
It is understood and agreed between the Parties that any payments made and any other consideration given under this Agreement
are each exclusive of any value added or similar tax (“VAT”), which shall be added thereon as applicable and
at the relevant rate. Subject to Section 8.16(b), where VAT is properly charged by the supplying Party and added to a payment
made or other consideration provided (as applicable) under this Agreement, the Party making the payment or providing the other
consideration (as applicable) will pay the amount of VAT properly chargeable only on receipt of a valid tax invoice from the supplying
Party issued in accordance with the laws and regulations of the country in which the VAT is chargeable. Each Party agrees that
it shall provide to the other Party any information and copies of any documents within its Control to the extent reasonably requested
by the other Party for the purposes of (i) determining the amount of VAT chargeable on any supply made under this Agreement, (ii)
establishing the place of supply for VAT purposes, or (iii) complying with its VAT reporting or accounting obligations.

 

    	 	21	 

     

    

 

(b)
Where one Party or its Affiliate (the “First Party”) is treated as making supply of goods or services in a
particular jurisdiction (for VAT purposes) for no consideration, and the other Party or its Affiliate (the “Second Party”)
is treated as receiving such supply in the same jurisdiction, thus resulting in an amount of VAT being properly chargeable on
such supply, the Second Party shall only be obliged to pay to the First Party the amount of VAT properly chargeable on such supply
(and no other amount). The Second Party shall pay such VAT to the First Party on receipt of a valid VAT invoice from the First
Party (issued in accordance with the laws and regulations of the jurisdiction in which the VAT is properly chargeable). Each Party
agrees to (i) use its reasonable efforts to determine and agree the value of the supply that has been made and, as a result, the
corresponding amount of VAT that is properly chargeable and (ii) provide to the other Party any information or copies of documents
in its Control as are reasonably necessary to evidence that such supply will take, or has taken, place in the same jurisdiction
(for VAT purposes).

 

9.
Confidentiality.

 

9.1.
Confidential Information. Subject to Section 13.4.8, Company and Merck agree to hold in confidence any Confidential
Information provided by or on behalf of the other Party, and neither Party shall use Confidential Information of the other Party
except to fulfill such Party’s obligations under this Agreement or exercising its rights. Without limiting the foregoing,
the Receiving Party may not, without the prior written permission of the Disclosing Party, disclose any Confidential Information
of the Disclosing Party to any Third Party except to the extent disclosure (i) is required by Applicable Law; (ii) is pursuant
to the terms of this Agreement; or (iii) is necessary for the conduct of the Study, and in each case ((i) through (iii)) provided
that the Receiving Party shall provide reasonable advance notice to the Disclosing Party before making such disclosure. For
the avoidance of doubt, Company may, without Merck’s consent, disclose Confidential Information to clinical trial sites
and clinical trial investigators performing the Study, the data safety monitoring and advisory board relating to the Study, and
Regulatory Authorities working with Company on the Study, in each case to the extent necessary for the performance of the Study
and provided that such Persons (other than governmental entities) are bound by an obligation of confidentiality at least
as stringent as the obligations contained herein.

 

9.2.
Inventions. Notwithstanding the foregoing: (i) Inventions that constitute Confidential Information and are jointly
owned by the Parties, shall constitute the Confidential Information of both Parties and each Party shall have the right to use
and disclose such Confidential Information consistent with Articles 10, 11 and 12; and (ii) Inventions that
constitute Confidential Information and are solely owned by one Party shall constitute the Confidential Information of that Party
and each Party shall have the right to use and disclose such Confidential Information consistent with Articles 10, 11
and 12.

 

    	 	22	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

9.3.
Personal Identifiable Data. All Confidential Information containing personal identifiable data shall be handled
in accordance with all data protection and privacy laws, rules and regulations applicable to such data.

 

10.
Intellectual Property.

 

10.1.
Joint Ownership and Prosecution.

 

10.1.1.
All rights to all Inventions relating to, or covering, [*****] (each a “Jointly Owned Invention”) shall be
owned jointly by Company and Merck. Merck hereby assigns to Company an undivided one-half interest in, to and under the Jointly
Owned Inventions that are invented or created solely by Merck or by Persons having an obligation to assign such rights to Merck.
Company hereby assigns to Merck an undivided one-half interest in, to and under any Jointly Owned Inventions that are invented
or created solely by Company or by Persons having an obligation to assign such rights to Company. For those countries where a
specific license is required for a joint owner of a Jointly Owned Invention to practice such Jointly Owned Invention in such countries:
(a) Merck hereby grants to Company a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable
and sublicensable, under Merck’s right, title and interest in and to all Jointly Owned Inventions to use such Inventions
in accordance with the terms of this Agreement; and (b) Company hereby grants to Merck a perpetual, irrevocable, non-exclusive,
worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under Company’s right, title and interest
in and to all Jointly Owned Inventions to use such Inventions in accordance with the terms of this Agreement. For clarity, the
terms of this Agreement do not provide Company or Merck with any rights, title or interest or any license to the other Party’s
intellectual property except as necessary to conduct the Study and as expressly provided under this Agreement, including as set
forth in Section 10.4.

 

10.1.2.
Each Party shall have the right to [*****].

 

10.1.3.
Promptly following the Effective Date, but in any event as soon as practicable after the discovery of a Jointly Owned Invention,
patent representatives of each of the Parties shall meet (in person or by telephone) to discuss the patenting strategy for any
Jointly Owned Inventions that may arise. In particular, the Parties shall discuss which Party will file and prosecute a patent
application (including any provisional, substitution, divisional, continuation, continuation in part, reissue, renewal, reexamination,
extension, supplementary protection certificate and the like) in respect of any Jointly Owned Invention (each, a “Joint
Patent Application”) and whether the Parties wish to appoint counsel that is mutually acceptable to the Parties. In
any event, the Parties shall consult and reasonably cooperate with one another in the preparation, filing, prosecution (including
prosecution strategy) and maintenance of such patent application and shall equally share the expenses associated with the Joint
Patent Applications and any corresponding Joint Patents. In the event that one Party (the “Filing Party”) wishes
to file a patent application for a Jointly Owned Invention and the other Party (the “Non-Filing Party”) does
not want to file a patent application for such Jointly Owned Invention or does not want to file in a particular country, the Non-Filing
Party shall execute in a timely manner and at the Filing Party’s reasonable expense an assignment of such Jointly Owned
Invention to the Filing Party (in such country or all countries, as applicable) and any additional documents as may be reasonably
necessary to allow the Filing Party to file and prosecute such patent application. If a Party (the “Opting-out Party”)
wishes to discontinue the prosecution and maintenance (or sharing in the costs with respect thereto) of a Joint Patent Application
or Joint Patent (in one or more countries), the other Party, at its sole option (the “Continuing Party”), may
continue such prosecution and maintenance. In such event, the Opting-out Party shall execute in a timely manner and at the Continuing
Party’s reasonable expense an assignment of such Joint Patent Application or Joint Patent to the Continuing Party (in such
country or all countries, as applicable) and any additional documents as may be necessary to allow the Continuing Party to prosecute
and maintain such Joint Patent Application or Joint Patent. Any Jointly Owned Invention, Joint Patent Application or Joint Patent
so assigned shall thereafter be owned solely by the Continuing Party or Filing Party (as applicable), shall no longer be considered
jointly owned, and the Non-Filing Party or Opting-out Party (as applicable) shall have no right to practice under such Joint Patent
Application or Joint Patent in the applicable country or countries.

 

    	 	23	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

10.1.4.
Except as expressly provided in Section 10.1.3 and in furtherance and not in limitation of Section 9.1, each Party
agrees to make no patent application based on the other Party’s Confidential Information, and to give no assistance to any
Third Party for such application, without the other Party’s prior written authorization.

 

10.1.5.
Company shall have the first right to initiate legal action to enforce all Joint Patents against infringement and to protect all
Jointly Owned Inventions from misappropriation by any Third Party, where [*****] or to defend any declaratory judgment action
relating thereto, at its sole expense. In the event that Company fails to initiate or defend such action within thirty (30) days
after being first notified of such infringement, Merck shall have the right to do so at its sole expense. Merck shall have the
first right to initiate legal action to enforce all Joint Patents against infringement and to protect all Jointly Owned Inventions
from misappropriation by any Third Party, where [*****] or to defend any declaratory judgment action relating thereto, at its
sole expense. In the event that Merck fails to initiate or defend such action within thirty (30) days after being first notified
of such infringement, Company shall have the right to do so at its sole expense. The Parties shall cooperate in good faith to
coordinate legal action to enforce all Joint Patents against infringement, and to protect all Jointly Owned Inventions from misappropriation,
by any Third Party where [*****] or to defend any declaratory judgment action relating thereto, and shall share the costs and
expenses of such litigation equally. Any damages or other monetary awards recovered shall be shared as follows: (a) the amount
of such recovery actually received by the Party controlling such action shall be first applied to the out-of-pocket costs of each
Party in connection with such action; and then (b) any remaining proceeds shall be divided evenly between Company and Merck.

 

10.1.6.
If one Party brings any prosecution or enforcement action or proceeding against a Third Party with respect to any Joint Patent,
the second Party agrees to be joined as a party plaintiff where necessary and to give the first Party reasonable assistance and
authority to file and prosecute the suit. The costs and expenses of the Party bringing suit under this Section 10.1.6 shall
be borne by such Party, and any damages or other monetary awards recovered shall be shared as follows: (a) the amount of such
recovery actually received by the Party controlling such action shall be first applied to the out-of-pocket costs of each Party
in connection with such action; and then (b) any remaining proceeds shall be divided evenly between Company and Merck. A settlement
or consent judgment or other voluntary final disposition of a suit under this Section 10.1.6 may not be entered into without
the consent of the Party not bringing the suit.

 

10.2.
Inventions Owned by Company. Notwithstanding anything to the contrary contained in Section 10.1, the Parties
agree that all rights to Inventions relating [*****], or covering [*****], regardless of whether such Invention or improvement
was invented solely by Company or Merck or jointly by the Parties, are the exclusive property of Company (“Company Inventions”).
Company shall be entitled to file and prosecute in its own name relevant patent applications and to own resultant patent rights
for any Company Invention. For the avoidance of doubt, any Invention [*****], is a Company Invention. Merck hereby assigns its
right, title and interest to any and all Company Inventions to Company.

 

10.3.
Inventions Owned by Merck. Notwithstanding anything to the contrary contained in Section 10.1, the Parties
agree that all rights to Inventions relating [*****], or covering [*****], regardless of whether such Invention or improvement
was invented solely by Merck or Company or jointly by the Parties, are the exclusive property of Merck (“Merck Inventions”).
Merck shall be entitled to file and prosecute in its own name relevant patent applications and to own resultant patent rights
for any Merck Invention. For the avoidance of doubt, any Invention [*****], even where [*****], is a Merck Invention. Company
hereby assigns its right, title and interest to any and all Merck Inventions to Merck.

 

10.4.
Mutual Freedom to Operate for Combination Inventions.

10.4.1.
Company License to Merck. Company hereby grants to Merck a non-exclusive, worldwide, royalty-free, fully paid-up, transferable
and sublicensable license to any patent Controlled by Company, including composition of matter and method patents, that [*****]
(the “Company Background Patents”) solely for [*****]; provided, however, that in no event shall
Merck have the right to use Company Background Patents to commercialize the Company Compound or any Company Class Compound.

 

10.4.2.
Merck License to Company. Merck hereby grants to Company a non-exclusive, worldwide, royalty-free, fully paid-up, transferable
and sublicensable license to any patent Controlled by Merck that [*****] (the “Merck Background Patents”) solely
for [*****]; provided, however, that in no event shall Company have the right to use Merck Background Patents to
commercialize the Merck Compound or any PD-1 Antagonist.

 

10.4.3.
No Other Rights. For clarity, the terms of this Section 10.4 do not provide Merck or Company with any rights, title
or interest or any license to the other Party’s intellectual property rights which [*****].

 

10.4.4.
Termination. Any and all licenses granted under this Section 10.4 shall [*****].

 

    	 	24	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

11.
Reprints; Rights of Cross-Reference.

 

Consistent
with applicable copyright and other laws, each Party may use, refer to, and disseminate reprints of scientific, medical and other
published articles and materials from journals, conferences and/or symposia relating to the Study that disclose the name of a
Party, provided, however, that such use does not constitute an endorsement of any commercial product or service
by the other Party.

 

12.
Publications; Press Releases.

 

12.1.
Clinical Trial Registry. Company shall register the Study with the Clinical Trials Registry located at www.clinicaltrials.gov
and is committed to timely publication of the results following Study Completion, after taking appropriate action to secure intellectual
property rights (if any) arising from the Study. The publication of the results of the Study will be in accordance with the Protocol.

 

12.2.
Publication. Each Party shall use reasonable efforts to publish or present scientific papers dealing with the Study
in accordance with accepted scientific practice. The Parties agree that prior to submission of the results of the Study for publication
or presentation or any other dissemination of such results including oral dissemination, the publishing Party shall invite the
other to comment on the content of the material to be published, presented, or otherwise disseminated according to the following
procedure:

 

12.2.1.
At least [*****] days prior to submission for publication of any paper, letter or any other publication, or [*****] days prior
to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to
the other Party the full details of the proposed publication, presentation, or dissemination in an electronic version (cd-rom
or email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation/dissemination
for an additional [*****] days in order to allow for actions to be taken to preserve rights for patent protection.

 

12.2.2.
The publishing Party shall give reasonable consideration to any request by the other Party made within the periods mentioned in
Section 12.2.1 to modify the publication and the Parties shall work in good faith and in a timely manner to resolve any
issue regarding the content for publication.

 

12.2.3.
The publishing Party shall remove all Confidential Information of the other Party before finalizing the publication.

 

12.3.
Press Releases. Promptly following the Effective Date, Company may issue the press release attached hereto as Appendix
C. Unless otherwise required by Applicable Law (including applicable regulations of a stock exchange on which either Party’s
securities are listed), neither Party shall make any other public announcement concerning this Agreement without the prior written
consent of the other Party. To the extent a Party desires to make such public announcement, such Party shall provide the other
Party with a draft thereof at least seven (7) Business Days prior to the date on which such Party would like to make the public
announcement, unless a shorter time period is required to comply with Applicable Law (including applicable regulations of a stock
exchange on which such Party’s securities are listed), in which case, the Party intending to make such public announcement
shall provide the other Party with as much advance notice as is reasonably practicable.

 

    	 	25	 

     

    

 

13.
Representations and Warranties; Disclaimers.

 

13.1.
Due Authorization. Each of Company and Merck represents and warrants to the other that: (a) it has the corporate
power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (b) it has taken all
necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance
of its obligations hereunder; and (c) this Agreement has been duly executed and delivered on behalf of such Party and constitutes
a legal, valid and binding obligation of such Party that is enforceable against it in accordance with its terms.

 

13.2.
Compounds.

 

13.2.1.
Company Compound. Company hereby represents and warrants to Merck that: (a) Company has the full right, power and authority
to grant all of the licenses granted to Merck under this Agreement; and (b) Company Controls the Company Compound.

 

13.2.2.
Merck Compound. Merck hereby represents and warrants to Company that: (a) Merck has the full right, power and authority
to grant all of the licenses granted to Company under this Agreement; and (b) Merck Controls the Merck Compound.

 

13.3.
Results. Company does not undertake that the Study shall lead to any particular result, nor is the success of the
Study guaranteed. Neither Party shall be liable for any use that the other Party may make of the Clinical Data nor for advice
or information given in connection therewith.

 

13.4.
Anti-Corruption.

 

13.4.1.
In performing their respective obligations hereunder, the Parties acknowledge that the corporate policies of Company and Merck
and their respective Affiliates require that each Party’s business be conducted within the letter and spirit of the law.
By signing this Agreement, each Party agrees to conduct the business contemplated herein in a manner that is consistent with all
Applicable Law, including the Stark Act, Anti-Kickback Statute, Sunshine Act, and the U.S. Foreign Corrupt Practices Act, good
business ethics, and its ethics and other corporate policies and agrees to abide by the spirit of the other Party’s guidelines,
which may be provided by such other Party from time to time.

 

13.4.2.
Specifically, each Party represents and warrants that it has not, and covenants that it, its Affiliates, and its and its Affiliates’
directors, employees, officers, and anyone acting on its behalf, will not, in connection with the performance of this Agreement,
directly or indirectly, make, promise, authorize, ratify or offer to make, or take any action in furtherance of, any payment or
transfer of anything of value for the purpose of influencing, inducing or rewarding any act, omission or decision to secure an
improper advantage; or improperly assisting it in obtaining or retaining business for it or the other Party, or in any way with
the purpose or effect of public or commercial bribery.

 

    	 	26	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

13.4.3.
Neither Party shall contact, or otherwise knowingly meet with, any Government Official for the purpose of discussing activities
arising out of or in connection with this Agreement, without the prior written approval of the other Party, except where such
meeting is consistent with the purpose and terms of this Agreement and in compliance with Applicable Law.

 

13.4.4.
Each Party represents and warrants that (a) it is not excluded, debarred, suspended, proposed for suspension or debarment, in
Violation or otherwise ineligible for government programs; and (b) it has not employed or subcontracted with any Person for the
performance of the Study who is excluded, debarred, suspended, proposed for suspension or debarment, or is in Violation or otherwise
ineligible for government programs.

 

13.4.5.
Each Party represents and warrants that, except as disclosed to the other in writing prior to the Effective Date, such Party:
(a) does not have any interest that conflicts with its proper and ethical performance of this Agreement; (b) shall maintain arm’s
length relations with all Third Parties with which it deals for or on behalf of the other in performance of this Agreement; and
(c) has provided complete and accurate information and documentation to the other Party, the other Party’s Affiliates and
its and their personnel in the course of any due diligence conducted by the other Party for this Agreement, including disclosure
of any officers, employees, owners or Persons directly or indirectly retained by such Party in relation to the performance of
this Agreement who are Government Officials or relatives of Government Officials. Each Party shall make all further disclosures
to the other Party as are necessary to ensure the information provided remains complete and accurate throughout the Term. Subject
to the foregoing, each Party agrees that it shall not hire or retain any Government Official to assist in its performance of this
Agreement, with the sole exception of conduct of or participation in clinical trials under this Agreement, provided that
such hiring or retention shall be subject to the completion by the hiring or retaining Party of a satisfactory anti-corruption
and bribery (e.g., FCPA) due diligence review of such Government Official. Each Party further covenants that any future information
and documentation submitted to the other Party as part of further due diligence or a certification shall be complete and accurate.

 

13.4.6.
Each Party shall have the right during the Term, [*****], to conduct an investigation and audit of the other Party’s activities,
books and records, to the extent they relate to that other Party’s performance under this Agreement, to verify compliance
with the terms of this Section 13.4. Such other Party shall cooperate fully with such investigation or audit, the scope,
method, nature and duration of which shall be at the sole reasonable discretion of the Party requesting such audit.

 

13.4.7.
Each Party shall use commercially reasonable efforts to ensure that all transactions under the Agreement are properly and accurately
recorded in all material respects on its books and records and that each document upon which entries in such books and records
are based is complete and accurate in all material respects. Each Party further represents, warrants and covenants that all books,
records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete and accurate
and reflect in reasonable detail the character and amount of transactions and expenditures. Each Party shall maintain a system
of internal accounting controls reasonably designed to ensure that no off-the-books or similar funds or accounts will be maintained
or used in connection with this Agreement.

 

    	 	27	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

13.4.8.
Each Party agrees that in the event that the other Party believes in good faith that there has been a possible material violation
of any provision of Section 13.4, such other Party may make full disclosure of such belief and related information needed
to support such belief at any time and for any reason to any competent government bodies and agencies, and to anyone else such
Party determines in good faith has a legitimate need to know.

 

13.4.9.
Each Party shall comply with its own ethical business practices policy and any corporate integrity agreement (if applicable) to
which it is subject, and shall conduct its Study-related activities in accordance with Applicable Law. Each Party shall ensure
that all of its employees involved in performing its obligations under this Agreement are made specifically aware of the compliance
requirements under this Section 13.4. In addition, each Party shall ensure that all such employees participate in and complete
mandatory compliance training to be conducted by each Party, including specific training on anti-bribery and corruption, prior
to his/her performance of any obligations or activities under this Agreement. Each Party shall certify its continuing compliance
with the requirements under this Section 13.4 on a periodic basis during the Term in such form as may be reasonably specified
by the other Party.

 

13.4.10.
Each Party shall have the right to terminate this Agreement immediately upon violation of this Section 13.4 in accordance
with Section 6.6.

 

13.5.
DISCLAIMER. EXCEPT AS EXPRESSLY PROVIDED HEREIN, MERCK MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE MERCK COMPOUND, AND COMPANY MAKES NO WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE COMPANY COMPOUND.

 

14.
Insurance; Indemnification; Limitation of Liability.

 

14.1.
Insurance. Each Party warrants that it maintains a policy or program of insurance or self-insurance at levels sufficient
to support the indemnification obligations assumed herein. Upon request, a Party shall provide evidence of such insurance.

 

14.2.
Indemnification.

 

14.2.1.
Indemnification by Company. Company agrees to defend, indemnify and hold harmless Merck, its Affiliates, and its and their
employees, directors, subcontractors and agents from and against any loss, damage, reasonable costs and expenses (including reasonable
attorneys’ fees and expenses) incurred in connection with any claim, proceeding, or investigation by a Third Party arising
out of [*****] (a “Liability”), except to the extent that such Liability [*****].

 

14.2.2.
Indemnification by Merck. Merck agrees to defend, indemnify and hold harmless Company, its Affiliates, and its and their
employees, directors, subcontractors and agents from and against any Liability to the extent such Liability was directly caused
by (a) negligence or willful misconduct on the part of Merck (or any of its Affiliates, or its and their employees, directors,
subcontractors or agents); (b) a breach on the part of Merck of any of its representations and warranties or any other covenants
or obligations of Merck under this Agreement; or (c) a breach of Applicable Law by Merck.

 

    	 	28	 

     

    

 

14.2.3.
Procedure. The obligations of Merck and Company under this Section 14.2 are conditioned upon the delivery of written
notice to Merck or Company, as the case might be, of any potential Liability within a reasonable time after a Party becomes aware
of such potential Liability. The indemnifying Party will have the right to assume the defense of any suit or claim related to
the Liability (using counsel reasonably satisfactory to the indemnified Party) if it has assumed responsibility for the suit or
claim in writing; provided that the indemnified Party may assume the responsibility for such defense to the extent the
indemnifying Party does not do so in a timely manner). The indemnified Party may participate in (but not control) the defense
thereof at its sole cost and expense. The Party controlling such defense (the “Defending Party”) shall keep
the other Party (the “Other Party”) advised of the status of such action, suit, proceeding or claim and the
defense thereof and shall consider recommendations made by the Other Party with respect thereto. The Defending Party shall not
agree to any settlement of such action, suit, proceeding or claim without the prior written consent of the Other Party, which
shall not be unreasonably withheld. The Defending Party, but solely to the extent the Defending Party is also the indemnifying
Party, shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof
that does not include a complete and unconditional release of the Other Party from all liability with respect thereto or that
imposes any liability or obligation on the Other Party without the prior written consent of the Other Party.

 

14.2.4.
Study Subjects. Company shall not offer compensation on behalf of Merck to any Study subject or bind Merck to any indemnification
obligations in favor of any Study subject. Merck shall not offer compensation on behalf of Company to any Study subject or bind
Company to any indemnification obligations in favor of any Study subject.

 

14.3.
LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES OR SUBCONTRACTORS) BE LIABLE TO
THE OTHER PARTY UNDER ANY THEORY FOR, NOR SHALL ANY INDEMNIFIED PARTY HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL,
CONSEQUENTIAL OR OTHER SIMILAR DAMAGES OR ANY PUNITIVE DAMAGES OR ANY LOST PROFIT, LOST SALE OR LOST OPPORTUNITY DAMAGES (WHETHER
SUCH CLAIMED DAMAGES ARE DIRECT OR INDIRECT), WHETHER ARISING DIRECTLY OR INDIRECTLY OUT OF (X) THE MANUFACTURE OR USE OF ANY
COMPOUND SUPPLIED HEREUNDER OR (Y) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT OR ANY REPRESENTATION,
WARRANTY OR COVENANT CONTAINED IN OR MADE PURSUANT TO THIS AGREEMENT, EXCEPT THAT SUCH LIMITATION SHALL NOT APPLY TO DAMAGES PAID
OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION HEREUNDER OR
WITH RESPECT TO DAMAGES ARISING OUT OF OR RELATED TO A PARTY’S BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT WITH RESPECT
TO USE, DISCLOSURE, LICENSE, ASSIGNMENT OR OTHER TRANSFER OF CLINICAL DATA, CONFIDENTIAL INFORMATION, JOINTLY-OWNED INVENTIONS
AND SAMPLE TESTING RESULTS.

 

    	 	29	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

15.
Use of Name.

 

Except
as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation
of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance
of this Agreement without the other Party’s prior written consent.

 

16.
Force Majeure.

 

If,
in the performance of this Agreement, one of the Parties is prevented, hindered or delayed by reason of any cause beyond such
Party’s reasonable control (e.g., war, riots, fire, strike, acts of terror, governmental laws), such Party shall be excused
from performance to the extent that it is necessarily prevented, hindered or delayed (“Force Majeure”). The
non-performing Party shall notify the other Party of such Force Majeure within [*****] days after such occurrence by giving written
notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize
its effect. The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing
Party shall use commercially reasonable efforts to remedy its inability to perform.

 

17.
Entire Agreement; Amendment; Waiver.

 

This
Agreement, together with the Appendices and Schedules hereto and the Related Agreements, constitutes the sole, full and complete
agreement by and between the Parties with respect to the subject matter of this Agreement, and all prior agreements, understandings,
promises and representations, whether written or oral, with respect thereto are superseded by this Agreement. In the event of
a conflict between a Related Agreement and this Agreement, the terms of this Agreement shall control. No amendments, changes,
additions, deletions or modifications to or of this Agreement shall be valid unless reduced to writing and signed by the Parties
hereto. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof,
but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving
such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other
Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether
of a similar nature or otherwise.

 

18.
Assignment and Affiliates.

 

Neither
Party shall assign or transfer this Agreement without the prior written consent of the other Party; provided, however,
that either Party may assign all or any part of this Agreement to one or more of its Affiliates without the other Party’s
consent, and any and all rights and obligations of either Party may be exercised or performed by its Affiliates, provided
that such Affiliates agree to be bound by this Agreement.

 

19.
Invalid Provision.

 

If
any provision of this Agreement is held to be illegal, invalid or unenforceable, the remaining provisions shall remain in full
force and effect and will not be affected by the illegal, invalid or unenforceable provision. In lieu of the illegal, invalid
or unenforceable provision, the Parties shall negotiate in good faith to agree upon a reasonable provision that is legal, valid
and enforceable to carry out as nearly as practicable the original intention of the entire Agreement.

 

    	 	30	 

     

    

 

20.
No Additional Obligations.

 

Company
and Merck have no obligation to renew this Agreement or apply this Agreement to any clinical trial other than the Study. Nothing
in this Agreement obligates the Parties to enter into any other agreement (other than the Related Agreements) at this time or
in the future.

 

21.
Governing Law; Dispute Resolution.

 

21.1.
The Parties shall attempt in good faith to settle all disputes arising out of or in connection with this Agreement in an amicable
manner. Any claim, dispute or controversy arising out of or relating to this Agreement, including the breach, termination or validity
hereof or thereof, shall be governed by and construed in accordance with the substantive laws of the State of New York, without
giving effect to its choice of law principles.

 

21.2.
Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court
of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed
or maintained notwithstanding any ongoing discussions between the Parties.

 

22.
Notices.

 

All
notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by
facsimile (and promptly confirmed by personal delivery or overnight courier), or sent by internationally-recognized overnight
courier addressed as follows:

If
to Company, to:

 

OncoSec
Medical Incorporated

5820
Nancy Ridge Drive

San
Diego, CA 92121

Attention: Legal Department

With
a copy to:

 

If
to Merck, to:

 

MSD
International GmbH

Weystrasse 20

6000 Luzern 6

Switzerland

Attention:

Facsimile:

 

With
copies (which shall not constitute notice) to:

 

    	 	31	 

     

    

 

23.
Relationship of the Parties.

 

The
relationship between the Parties is and shall be that of independent contractors, and does not and shall not constitute a partnership,
joint venture, agency or fiduciary relationship. Neither Party shall have the authority to make any statements, representations
or commitments of any kind, or take any actions, that are binding on the other Party, except with the prior written consent of
the other Party to do so. All Persons employed by a Party will be the employees of such Party and not of the other Party and all
costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party.

 

24.
Counterparts and Due Execution.

 

This
Agreement and any amendment may be executed in any number of counterparts (including by way of facsimile or electronic transmission),
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, notwithstanding
any electronic transmission, storage and printing of copies of this Agreement from computers or printers. When executed by the
Parties, this Agreement shall constitute an original instrument, notwithstanding any electronic transmission, storage and printing
of copies of this Agreement from computers or printers. For clarity, facsimile signatures and signatures transmitted via PDF shall
be treated as original signatures.

 

25.
Construction.

 

Except
where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, the use of
any gender will be applicable to all genders, and the word “or” is used in the inclusive sense (and/or). Whenever
this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this
Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement
or the intent of any provision contained in this Agreement. The term “including” as used herein shall be deemed
to be followed by the phrase “without limitation” or like expression. The term “will” as
used herein means shall. The terms “hereof”, “hereto”, “herein” and “hereunder”
and words of similar import when used in this Agreement refer to this Agreement as a whole and no to any particular provision
of this Agreement. References to “Article,” “Section”, “Appendix” or
“Schedule” are references to the numbered sections of this Agreement and the appendices attached to this Agreement,
unless expressly stated otherwise. Except where the context otherwise requires, references to this “Agreement”
shall include the appendices attached to this Agreement. The language of this Agreement shall be deemed to be the language mutually
chosen by the Parties and no rule of strict construction will be applied against either Party hereto.

 

[Remainder
of page intentionally left blank.]

 

    	 	32	 

     

    

 

IN
WITNESS WHEREOF, the respective representatives of the Parties have executed this Agreement as of the Effective Date.

 

	OncoSec
    Medical Incorporated
	 	 
	By:
    	/s/
    Punit Dhillon	 
		Punit
    Dhillon	 
	Name	 	 
		President
    and Chief Executive Officer	 
	Title	 	 
	 	 	 
	MSD
    International GmbH
	 	 
	By:
    	/s/
    Franz Escherich	 
		Franz
    Escherich	 
	Name	 	 
		Director	 
	Title	 	 

 

    	 	33	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

Appendix
A

 

PROTOCOL
SYNOPSIS

 

	Study
    Title	 	The
    PISCES Study: A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 plus Electroporation in Combination with Intravenous
    Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
	 	 	 
	Protocol
    No.	 	OMS-I103
	 	 	 
	[*****]	 	[*****]
	 	 	 
	Study
    Phase	 	2
	 	 	 
	Therapeutic
    Indication	 	Intratumoral
    injection of plasmid interleukin-12 followed by electroporation (ImmunoPulse® IL-12), in combination with an anti-programmed
    cell death protein 1 (PD-1) antibody pembrolizumab, is indicated for the treatment of unresectable or metastatic melanoma.

 

	Study
    Objectives	 	●	To
    assess efficacy of best overall response rate (BORR) by independent central review based on RECIST v1.1 over 24 weeks (end
    of Core study) of intratumoral pIL-12-EP in combination with pembrolizumab (IV) (collectively ‘the combined treatment’)
    in patients with unresectable or metastatic melanoma who previously have progressed on prior approved anti-PD-1 antibodies
    (either as monotherapy or in combination with other approved checkpoint inhibitor.
	 	 	 	 
	 	 	●	To
    assess safety and tolerability of the combined treatment in patients with unresectable or metastatic melanoma who previously
    have progressed on prior approved anti-PD-1 antibodies (either as monotherapy or in combination with other approved checkpoint
    inhibitor).
	 	 	 	 
	 	 	●	To
    assess duration of response (DOR), objective response rate (ORR), immune BORR (iBORR), progression free survival (PFS), immune
    PFS (iPFS), and overall survival (OS) of combination therapy;
	 	 	 	 
	 	 	●	[*****]

 

	Investigational
    Product Route and Dosage Form	 	Plasmid
                                         interleukin-12 (pIL-12) will be injected intratumorally (on Days 1, 5 and 8 every 6 weeks)
                                         [*****]

        Pembrolizumab
        will be administered at a dose of 200 mg [*****]

	 	 	 
	Study
    Design 	 	This
                                         will be a Phase 2, Simon 2-stage minimax design, non-comparative, open-label, single-arm,
                                         multicenter study of intratumoral pIL-12-EP plus IV pembrolizumab. Eligible patients
                                         will be those with pathological diagnosis of unresectable or metastatic melanoma who
                                         are progressing or have progressed on pembrolizumab or nivolumab (either as monotherapy
                                         or in combination with another approved checkpoint inhibitor confirmed according to RECIST
                                         v1.1. If a patient is BRAF V600 mutation positive, they must have received a BRAF inhibitor
                                         according to the approved label.

         

        The
        study will be comprised of a Core study (24 weeks), an Extension Phase and a long-term follow-up.

         

        Core
        study: Eligible patients will be treated with intratumoral pIL-12-EP to the accessible lesions on Days 1, 5 and 8
        every 6 weeks and with IV pembrolizumab (200 mg) [*****] for 24 weeks. [*****]

         

        Extension
        phase: Patients who completed 24 weeks of treatment (Core study) with the investigators discretion, will enter an
        Extension phase [*****]

	 	 	 
	Study
    Duration	 	The
    study duration for each individual patient will be 24 weeks in the Core study (excluding the screening period), up to 35 pembrolizumab
    cycles from baseline (approximately 2 years) in the Extension phase and long-term follow-up (until death, patient withdraw
    consent or sponsor terminates the study).
	 	 	 
	Immune
    Monitoring 	 	For
    Immune Monitoring, tumor biopsies (fixed and fresh) as well as blood and fecal samples will be collected [*****]
	 	 	 
	[*****]	 	[*****]

 

    	 	34	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

	Inclusion
    Criteria	 	In
    order to be eligible for participation in this trial, the patient must meet all the following:

 

	 	1.	Pathologically
    documented unresectable melanoma, AJCC Stage III or IV. Patients must have histological or cytological confirmed diagnosis
    of unresectable melanoma with progressive locally advanced or metastatic disease.
	 	 	 
		2.	Patients
    must be refractory to anti-PD-1 monoclonal antibodies (mAb) defined as pembrolizumab or nivolumab as either as monotherapy
    or in combination with other approved checkpoint inhibitors or targeted therapies according to their approved label, defined
    as (patients must meet all of the following criteria):

 

	 	a.	Received
    at least 4 doses of anti-PD1 mAb (minimum dose of 2 mg/kg given every three weeks (Q3W) for pembrolizumab; minimum dose of
    240 mg given every two weeks (Q2W) for nivolumab in monotherapy; minimum dose of 1 mg/kg given Q3W for nivolumab in combination
    with ipilimumab
	 	 	 
	 	b.	Progressive
    disease after anti-PD1 mAb will be defined according to RECIST v1.1. [*****]
	 	 	 
	 	c.	Documented
    disease progression within 24 weeks of the last dose of anti-PD1 mAb. Patients who were re-treated with anti-PD1 mAb and patients
    who were on maintenance with anti-PD1 mAb will be allowed to enter the trial as long as there is documented PD within 24 weeks
    of the last treatment date (with anti-PD1 mAb).

 

	 	3.	Resolution/improvement
    of anti-PD1 mAb-related [*****]

 

	 	a.	No
    history of common toxicity criteria adverse events (CTCAE) Grade 4 irAEs from anti-PD1 mAb.
	 	 	 
	 	b.	No
    history of CTCAE Grade 3 requiring steroid treatment. [*****]
	 	 	 
	 	c.	Minimum
    of 4 weeks (washout period) from the last dose of anti-PD1 mAb.

 

	 	4.	Prior
    treatment with an approved BRAF inhibitor if BRAF V600 mutation-positive.
	 	 	 
	 	5.	Age
    ≥ 18 years of age on day of signing informed consent.
	 	 	 
	 	6.	Has
    a performance status of 0 or 1 on the ECOG Performance Scale.
	 	 	 
	 	7.	Have
    measurable disease based on RECIST v1.1, with at least one anatomically distinct lesion. Lesion or lesions must meet all the
    following baseline criteria:

 

	 	a.	Accessible
    for electroporation,
	 	 	 
	 	b.	Must
    be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum
    size per RECIST v1.1.
	 	 	 
	 	[*****]

 

	 	8.	Demonstrate
    adequate organ function as defined below. All screening laboratories should be performed within 10 days of treatment initiation.

 

    	 	35	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

	 	System	 	Laboratory
    Value
	 	Hematological	 	 
	 	 	 	 
	 	Absolute
    neutrophil count (ANC)	 	≥1.5
    × 109/L
	 	Platelets	 	≥100
    × 109/L
	 	Hemoglobin	 	≥9
    g/dL or ≥5.6 mmol/L
	 	 	 	 
	 	Renal	 	 
	 	 	 	 
	 	Creatinine*
    OR	 	≤1.5
    × the upper limit of normal (ULN) OR
	 	Measured
    or calculated creatinine clearance (CrCl)	 	 
	 	Glomerular
    filtration rate (GFR) can also be used instead of creatinine or CrCl	 	≥
    60 mL/min for patient with creatinine levels >1.5 × institutional ULN
	 	 	 	 
	 	Hepatic	 	 
	 	 	 	 
	 	Total
    bilirubin	 	≤1.5
    × ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels > 1.5× ULN
	 	 	 	 
	 	Aspartate
    aminotransferase (AST) and alanine aminotransferase (ALT)	 	≤2.5
    × ULN OR ≤5 × ULN for patients with liver metastases
	 	 	 	 
	 	Coagulation
    	 	 
	 	 	 	 
	 	International
    Normalized Ratio (INR) or Prothrombin Time (PT)	 	≤1.5
    × ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended
    use of anticoagulants
	 	 	 	 
	 	Activated
    Partial Thromboplastin Time (aPTT)	 	 
	 	 	 	 
	 	*
    Creatinine clearance should be calculated per institutional standard.

 

	 	9.	Women
    of childbearing potential must have negative serum or urine pregnancy test within 72 hours prior to receiving the first study
    drug administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
	 	 	 
	 	 	For
    women of childbearing potential, must be willing to use an adequate method of contraception from 30 days prior to the first
    study drug administration and 120 days following last day study drug administration[*****]
	 	 	 
	 	10.	Male
    patients of childbearing potential must be surgically sterile, or must agree to use adequate method of contraception during
    the study and at least 120 days following the last day of study drug administration.
	 	 	[*****]
	 	 	 
	 	11.	Able
    and willing to provide written informed consent and to follow study instructions.

 

    	 	36	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

	Exclusion
    criteria	 	The
    patient must be excluded from participating in the trial if meet any of the following:

 

	 	1.	Patient
    has disease that is suitable for local therapy administered with curative intent.
	 	 	 
	 	2.	Patient
    with a diagnosis of uveal melanoma.
	 	 	 
	 	3.	Patient
    has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma
    of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
	 	 	 
	 	4.	Clinically
    active cerebral or any bone metastases. Patients with up to 3 (neurological performance status of 0) cerebral metastases may
    be enrolled, provided that all lesions have been adequately treated with stereotactic radiation therapy or gamma-knife therapy
    with no evidence of progression, and have not required steroids, for at least two months prior to enrolment.
	 	 	 
	 	5.	Greater
    than 3 visceral metastases (this does not include nodal metastases associated with visceral organs). For patients with less
    than or equal to 3 visceral metastases, no lesion > 3 cm and liver lesions must meet RECIST v1.1 criteria for SD for at
    least 1 month prior to enrolment.
	 	 	 
	 	6.	Patients
    with electronic pacemakers or defibrillators.
	 	 	 
	 	7.	Patients
    who have a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
	 	 	 
	 	8.	Patients
    who have known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [*****] is detected); Note:
    Patients who have been vaccinated against Hepatitis B and who are positive only for the Hepatitis B surface antibody are permitted
    to participate in the study.
	 	 	 
	 	9.	Patient
    has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy
    within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after
    consultation with the Sponsor.
	 	 	 
	 	10.	Patients
    who have received a live-virus vaccination within 30 days of the first dose of treatment. Seasonal flu vaccines that do not
    contain live virus are permitted.
	 	 	 
	 	11.	Patient
    has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
	 	 	 
	 	12.	Patients
    who have received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating
    factors (including G-CSF, GM-CSF or recombinant erythropoietin) within 4 weeks prior to study Cycle 1, Day 1 (baseline).
	 	 	 
	 	13.	Patient
    has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
	 	 	 
	 	14.	Patient
    has a history of interstitial lung disease.
	 	 	 
	 	15.	Patient
    has an active infection requiring systemic therapy.

 

    	 	37	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

	 	16.	Patient
    has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of
    the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest
    of the patient to participate, in the opinion of the treating investigator.
	 	 	 
	 	17.	Patient
    has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
	 	 	[*****]
	 	 	 
	 	18.	Participation
    in another clinical trial within 30 days of screening.
	 	 	[*****]
	 	 	 
	 	19.	Patients
    who have had any chemotherapy, targeted small molecule therapy, radiation therapy or any immunotherapeutic after their confirmed
    progression on anti-PD-1 therapy.
	 	 	 
	 	20.	Patient
    has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
	 	 	 
	 	21.	Patients
    who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial,
    starting with the screening visit through 120 days after the last dose of trial treatment.

 

	Efficacy
    Endpoints	 	Primary
    Efficacy Endpoint:

		●	BORR
    by [*****] RECIST v1.1 over 24 weeks

	 	 	Secondary
    Efficacy Endpoints:

	 	●	ORR
    [*****];
	 	●	DOR
    [*****];
	 	●	PFS
    [*****];
	 	●	[*****]
	 	 	OS.
	 	Exploratory
    Endpoint:47
	 	Immune
    monitoring [*****1]

 

	Safety	 	Safety
    assessments in the Core study and Extension phase will include:

	Assessments
     	●	AEs
	and
    Outcomes 	●	Pembrolizumab
    AE of event(s) of clinical interest (ECI)
	 	●	Safety
    Laboratory
	 	●	ECOG
    performance status
	 	●	Physical
    examination
	 	●	Vital
    signs
	 	●	Assessment
    of durable procedural pain
	 	●	Concomitant
    medication

 

 

 

1
[*****]

 

    	 	38	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

	 	 	Primary
    safety outcomes:

 

	 	1.	Frequency,
    duration and severity of AEs and serious AEs (SAEs);
	 	2.	Incidence
    and shifts of clinically significant laboratory abnormalities; safety laboratory evaluations includes complete blood count
    (CBC), blood biochemistry and urinalysis

 

	 	 	Safety
    outcome will be analyzed at end of Core study (24 weeks) and at the end of the study (EOS visit).
	 	 	 
	 	 	AEs
    and abnormal laboratories will be classified according to the National Cancer Institute - Common Terminology Criteria for
    Adverse Events (NCI-CTCAE), version 4.03. If a laboratory finding is abnormal but not clinically significant (NCS) at baseline,
    post-baseline laboratory abnormalities will be reported as an AE only if there is worsening compared to baseline.
	 	 	 
	 	 	Progression
    of the cancer under study is not considered an adverse event unless it is drug-related by the investigator.
	 	 	 
	[*****]	 	[*****]

 

    	 	39	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

Appendix
B

 

SUPPLY
OF COMPOUND

 

Schedule
of Deliveries for IT-pIL 12-EP

 

	Delivery
    Date	 	Quantity
    of Vials
	[*****]	 	[*****]
	[*****]	 	[*****]
	[*****]	 	[*****]
	 	 	[*****]

 

Schedule
of Deliveries for KEYTRUDA®

 

	Delivery
    Date	 	Quantity
                                         of Vials

        (Liquid
        – [*****] vial)

	[*****]	 	[*****]
	[*****]	 	[*****]
	 	 	[*****]

 

    	 	 

     

    

 

Appendix
C

 

COMPANY
PRESS RELEASE

 

OncoSec
Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab)
for Metastatic Melanoma

 

San
Diego, CA – April XX, 2017 — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, has entered a clinical trial collaboration and supply agreement with Merck (known
as MSD outside the United States and Canada) to evaluate the combination of OncoSec’s ImmuoPulse® IL-12 with Merck’s
anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase II clinical trial, referred to as PISCES. The planned clinical
trial will evaluate the safety and efficacy of the combination in patients with metastatic melanoma following disease progression
on previous treatment with an anti-PD-1 therapy.

 

“We
are honored to collaborate with Merck – one of the world’s leading cancer immuno-oncology companies – to help
bring innovative cancer treatments to patients with unmet medical needs,” said Punit Dhillon, CEO and President of OncoSec.
“This collaboration is supported by our recent clinical data demonstrating the potential ability of ImmunoPulse®
IL-12 to rescue patients who do not initially respond to anti-PD-1 therapy in melanoma. In addition to our recent Fast Track
Designation for this population, OncoSec is uniquely positioned to meaningfully impact clinical outcomes for patients who do not
currently have any other options. By working with innovative immuno-oncology leaders, this alliance underpins OncoSec’s
strategy to combine our ImmunoPulse® IL-12 program with checkpoint inhibitor therapies to advance the care of patients.”

 

Eligible
patients for this Phase II study will be those with Stage III/IV metastatic melanoma who are progressing, or have progressed,
on previous treatment with an anti-PD-1 therapy. . The collaboration agreement is between OncoSec Medical Incorporated and Merck,
through a subsidiary. Under the agreement, OncoSec will sponsor and fund the study and Merck will provide KEYTRUDA. Additional
details of the collaboration were not disclosed.

 

KEYTRUDA®
is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

 

ImmunoPulse®
is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.

 

About
PISCES

 

PISCES
(Anti-PD-1 IL-12 Stage III/IV Combination Electroporation
Study) will be a Phase II multicenter study of ImmunoPulse® IL-12 pin combination with KEYTRUDA® in patients
with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage
IV. Eligible patients will be those with Stage III/IV metastatic melanoma who are progressing or have progressed an approved anti-PD-1
therapy. The primary endpoint for this registration-directed trial will be best overall response rate (BORR).

 

    	 	 

     

    

 

About
OncoSec Medical Incorporated

 

OncoSec
is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®,
for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic clinical and immune response. OncoSec’s
lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast
cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory
or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing
new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

 

Cautionary
Note Regarding Forward-Looking Statements

 

This
press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements can be identified by words such as “can,” “may,” “will,”
“suggest,” “look forward to,” “potential,” “understand,” and similar references
to future periods.

 

Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current
preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely
from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted
include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the ability
to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability
to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec’s filings
with the Securities and Exchange Commission.

 

Undue
reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims
any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they
are made, or to reflect the occurrence of unanticipated events.

 

CONTACT:

 

Investor
Relations:

OncoSec
Medical Incorporated

855-662-6732

investors@oncosec.com

 

Media
Relations :

OncoSec
Medical Incorporated

855-662-6732

media@oncosec.com

 

    	 	 

     

    

 

Confidential
Treatment Requested. Omitted Portions are Marked with [*****] and have been Filed Separately with the Securities and Exchange
Commission.

 

Schedule
I

 

DATA
SHARING AND SAMPLE TESTING SCHEDULE

 

	Study
    Procedures	 	Shared
    between 

    the Two Parties	 	Not
    Shared	 	Timing
                                         to provide item

        (data/sample,
        etc.)
	 	Party
    to

    Analyze Data/Sample
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]
	[*****]	 	[*****]	 	 	 	[*****]	 	[*****]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]